

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Tachycardia does not imply an increased risk of mortality in trauma-related hemorrhagic shock - A Systematic Review and Meta-regression

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-059271
Article Type:	Original research
Date Submitted by the Author:	13-Nov-2021
Complete List of Authors:	Jávor, Péter; University of Szeged, Department of Traumatology Hanák, Lilla; Pécsi Tudományegyetem Általános Orvostudományi Kar Hegyi, Péter; Pécsi Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine Csonka, Endre; Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Department of Traumatology Butt, Edina; Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Department of Traumatology Horváth, Tamara; Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar Góg, István; Military Hospital, Department of Vascular Surgery Lukacs, Andrea; Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Department of Public Health Soós, Alexandra; Pécsi Tudományegyetem Általános Orvostudományi Kar Rumbus, Zoltán; Pécsi Tudományegyetem Általános Orvostudományi Kar, Department of Thermophysiology Pákai, Eszter; Pécsi Tudományegyetem Általános Orvostudományi Kar, Department of Thermophysiology Pákai, Eszter; Pécsi Tudományegyetem Általános Orvostudományi Kar, Department of Thermophysiology Toldi, János; Pécsi Tudományegyetem Általános Orvostudományi Kar, Department of Anesthesiology and Intensive Care Hartmann, Petra; University of Szeged, Department of Traumatology
Keywords:	Trauma management < ORTHOPAEDIC & TRAUMA SURGERY, Bleeding disorders & coagulopathies < HAEMATOLOGY, ORTHOPAEDIC & TRAUMA SURGERY, ACCIDENT & EMERGENCY MEDICINE

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

3
4
5
6
7
8
9
10
11
12
13
14
15
16 17
17
18
19
20
21
22
23
24
25
25
26 27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
45 46
47
48
49
50
51
52
53
54
55
55 56
57
58
59
60

TACHYCARDIA DOES NOT IMPLY AN INCREASED RISK OF MORTALITY IN 1 **TRAUMA-RELATED HEMORRHAGIC SHOCK - A SYSTEMATIC REVIEW AND META-REGRESSION**

Péter Jávor¹, Lilla Hanák², Péter Hegyi^{2;3}, Endre Csonka¹, Edina Butt¹, Tamara Horváth⁴, István 4 5 Góg⁵, Anita Lukács⁶, Alexandra Soós², Zoltán Rumbus⁷, Eszter Pákai⁷, János Toldi⁸, Petra

Hartmann^{1*} 6

2

3

- 7 ¹Department of Traumatology, University of Szeged, Szeged, Hungary
- 8 ² Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
- 9 ³Center for Translational Medicine, Department of Medicine, University of Szeged, Szeged, Hungary
- 10 ⁴Institute of Surgical Research, University of Szeged, Szeged, Hungary
- 11 ⁵ Department of Vascular Surgery, Hungarian Defense Forces Medical Center - Military Hospital, 12 Budapest, Hungary
- ⁶ Department of Public Health, Faculty of Medicine, University of Szeged, Szeged, Hungary 13
- ⁷ Department of Thermophysiology, Medical School, University of Pécs, Pécs, Hungary 14
- ⁸ Department of Anesthesiology and Intensive Care, Medical School, University of Pécs, Pécs, 15 iez oni
- 16 Hungary

22

17 *Correspondence

- 18 Petra Hartmann M.D., Ph.D.
- Semmelweis utca 6., Szeged, 6725 Hungary 19
- Tel: +(36-62) 545-531; Fax: +(36-62) 545-530 20
- 21 E-mail: hartmann.petra@med.u-szeged.hu
- 23 Word count (excluding title page, abstract, references, figures, and tables): 2868
- 24 Number of Tables: 2
- Number of Figures: 4 25

1 2		
2 3 4	26	ABSTRACT
5	27	Introduction: Heart rate (HR) is one of the physiologic variables in the early assessment of trauma-
6 7	28	related hemorrhagic shock, according to Advanced Trauma Life Support (ATLS). Regarding its
8 9	29	efficiency as a predictor of mortality, there is contradictory data in literature. Furthermore, the linear
9 10	30	association between HR and the severity of shock and blood loss presented by ATLS is doubtful. This
11 12	31	systematic review updates current knowledge on the role of HR in the initial hemodynamic assessment
13	32	of trauma patients.
14 15	33	Methods: A systematic search of EMBASE, MEDLINE, CENTRAL and Web of Science databases
16 17	34	was performed to identify papers providing early HR and mortality data on bleeding trauma patients
17	35	from the past decade. The association between HR and mortality of trauma patients was assessed using
19 20	36	meta-regression analysis. As a subgroup analysis, meta-regression was performed on patients who
21	37	received blood products.
22 23	38	Results: From a total of 2017 papers, 19 studies met our eligibility criteria. Our primary meta-regression
24	39	did not find a significant relation (p=0.847) between HR and mortality in trauma patients with
25 26	40	hemorrhage. Our subgroup analysis included 10 studies, and it could not reveal a linear association
27 28	41	between HR and mortality rate.
29	42	Conclusions: Tachycardia should raise suspicion for bleeding, but it might not be appropriate to guide
30 31	43	therapeutic decisions such as transfusion of blood products. In addition to the literature demonstrating
32	44	the multi-phasic response of HR to bleeding, our study presents the lack of linear association with
33 34	45	mortality. Considering these, modifying the pattern of HR derangements in the ATLS shock
35 36	46	classification may result in a more precise teaching tool for young clinicians.
37 38	47	Keywords: "tachycardia"; "heart rate"; "hemorrhagic shock"; "multiple trauma"; "ATLS"
39 40		
41 42	48	STRENGTHS AND LIMITATIONS OF THIS STUDY
43	49	• The study summarizes and analyzes scientific data from the past 10 years to investigate trauma-
44 45	50	related hemorrhage, an issue with high clinical importance.
46 47	51	• The paper provides a systematic search of EMBASE, MEDLINE (via PubMed), Cochrane
48	52	Controlled Register of Trials (CENTRAL) and Web of Science databases, utilizes rigorous
49 50	53	study selection criteria, assesses each enrolled paper for bias, and performs meat-regression
51 52	54	analyses.
53 54	55	• Studies focusing on special populations including pregnant, pediatric (<18 years of age),
55	56	geriatric (≥55 years), burned and traumatic spinal- or brain injured patients were excluded from
56 57	57	the study.
58 59	58	• The heterogeneity and the difference in patient number among the included studies prevented
60	59	us from performing an adequate meta-analysis.

60 INTRODUCTION

Hypovolemia caused by hemorrhage is the most common cause of shock in trauma. Delay in the recognition of shock has been linked to unfavorable outcomes such as organ dysfuntion and mortality.[1,2] The initial assessment of trauma-related hypovolemic shock is based on derangements of physiologic variables (including base deficit) according to the recommendations of Advanced Trauma Life Support (ATLS).[3] Among these variables, heart rate (HR) is one of the most controversial when it comes to blood loss.[4-7] As commonly criticized, HR is not only influenced by hemodynamic changes, but also by several other factors such as anxiety, pain, and medications resulting in a low specificity for hemorrhage.[4,8,9] Furthermore, ATLS suggests the continuously increasing tendency of HR in accordance with the severity of bleeding.[3] However, in clinical reality, the HR response to hemorrhage is rather biphasic or triphasic than linear.[8,10,11] Consequently, the utility of HR in the early management of bleeding trauma patients was called into doubt during the past decades. [4,5,8,9]

The reliability of HR was already questioned in the early 2000s by a retrospective analysis on 14325 trauma patients. According to the results of this study, HR displayed insufficient sensitivity and specificity in predicting hypotension after trauma.[9] A few years later, a registry analysis denoted further doubts in HR, as it had performed poorly in predicting the need for an emergent intervention and administration of packed red blood cells (pRBC) in the first 24 hours post-injury.[4] Additionally, as ATLS was progressively widespread, the role of HR in the classification of hypovolemic shock sparked controversy. In 2013, 16305 patients from the german trauma register (DGU®) were allocated into shock classes according to ATLS guidance.[12] Ultimately, no significant alterations in mean HR were found within the four classes. According to these data, expecting tachycardia in case of hypovolemia can be misleading in many instances. Moreover, a false sense of hemodynamic stability based on normal HR can lead to fatal consequences, since the lack of tachycardia in hypoperfusion is associated with poor prognosis.[13]

Despite criticism, increased HR has been known as a characteristic of hypovolemic shock for a very long time. The utility of HR as a predictor of mortality is supported by several papers.[14,15] An international, cross-sectional study using data from two large trauma cohorts was conducted to develop and validate a prognostic model to predict death due to bleeding. Although HR showed a significant relation to mortality, the curve was U-shaped as opposed to the linear model presented by ATLS.[15]

A notable limitation of previous studies is that trauma protocols have undergone several changes, which makes recent information incomparable with data from the past. In 2010, the CRASH-2 trial brought one of the most prominent findings of the past decades with the validation of the safeness and effectivity of tranexamic acid (TXA).[16-18]

The present systematic review investigates the role of HR in the initial assessment of trauma patients with hemorrhage. Regarding the efficiency of HR as a predictor of outcome in trauma, there is contradictory data in the literature.[4,5,15] Furthermore, the linear association between HR and blood Page 5 of 25

loss presented by ATLS is questionable.[8,15] Due to the development of trauma care and a paradigm shift in the initial fluid resuscitation approach in the past decades, [16,19] we aimed to update current knowledge on the effectivity of HR as predictor of mortality post-injury. For this purpose, a comprehensive database search has been conducted, data has been extracted and analyzed through meta-regressions. As a primary outcome, the relationship between HR and mortality has been assessed. Since the severity of bleeding has a close relation to the risk for adverse outcomes including increased organ dysfunction and mortality, our study may be able to initiate further research reappraising the validity of HR in the ATLS classification of hypovolemic shock.

104 MATERIALS AND METHODS

105 Protocol and search strategy

106 The present review is reported in accordance with Preferred Reporting Items for Systematic Reviews
107 and Meta-Analyses (PRISMA).[20] The PRISMA checklist for our work is available in the supporting
108 information (Table S1). The review protocol was registered in the Open Science Framework (OSF)
109 system under registration DOI: 10.17605/OSF.IO/HJWYR.

A systematic search of EMBASE, MEDLINE (via PubMed), Cochrane Controlled Register of Trials
(CENTRAL) and Web of Science databases was performed with the following search terms: "trauma"
AND ("heart rate" OR "pulse rate" OR "tachycardia" OR "bradycardia" OR "vital sign" OR "vital signs"
OR "vital parameter" OR "vital parameters") AND "mortality" AND ("bleeding" OR "haemorrhage"
OR "hemorrhage" OR "haemodynamic" OR "hemodynamic").

7 115 Eligibility criteria

Records on bleeding trauma patients were considered for eligibility only if they provided initial HR values (prehospital (PH) or upon admission (AD)) in addition to mortality data covering a time interval not exceeding 30 days from the time of injury. If the inclusion criteria of the individual studies included transfusion of blood products and/or positive focused assessment with sonography for trauma (FAST) examination and/or hemodinamical instability after trauma and/or abdominal gunshot injury, the patient cohort was considered hemorrhagic.

122 Non-English language reports, records on special populations such as pregnant, pediatric (<18 years of 123 age) or geriatric (\geq 55 years) were not considered. Studies on patients suffering burns, traumatic spinal 124 or- brain injuries were excluded.

Taking the development of trauma care in the past decade into consideration (e.g.: introduction of TXA,[16] and paradigm shift in fluid resuscitation [19]) all studies that included data on patients who received treatment before 2010 were also excluded.

58 128 Study selection

After having duplicates removed with the help of a reference manager software (EndNote X7), articles published before 2010 were also discarded. On the remaining studies, title and abstract screenings were performed by two review authors (PJ, IG). Thereafter, the full texts of the potentially eligible records were obtained and assessed based on the criteria described above. Disagreements were resolved by consensus.

Data extraction

The following information was extracted from the eligible studies: title, first author's name, year of publication, study design, data origin (country, hospital database/registry), data collection period, inclusion criteria, subgroups, patient number of the subgroups, total patient number, HR (mean ± standard deviation (SD) or median [interquartile range] (IQR)), phase of recording HR values (PH/AD), mortality within 30 days (n, %). In case of studies using overlapping data, the less comprehensive report with the smaller sample size was excluded.

Risk of bias assessment

Quality In Prognostic Studies (QUIPS) tool was used separately by two authors (TH and ZR) to assess the risk of bias for each study.[21] Disagreements were resolved by consensus. QUIPS consists of six main domains: 'Study attrition', 'Study participation', 'Prognostic factor', 'Outcome measurement', 'Study confounding' and 'Statistical analysis and reporting'. A rating for each domain was assigned as carrying 'low', 'moderate' or 'high' risk of bias. Based on the ratings of the individual domains, the overall risk of bias was evaluated by each study.

Statistical analysis

The association between HR and mortality of trauma patients was assessed using meta-regression analysis. A result of p < 0.05 was considered as significant. As a subgroup analysis, meta-regression was performed on trauma patients who received blood products. Statistical analyses were performed with Stata 16 (Stata Corp, College Station, TX, USA). To convert median values to means, we used the method of Xiang Wan.[22]

RESULTS

Results of systematic search and selection

Two thousand and seventeen records were identified through our search strategy on 1 September 2020. One thousand three hundred seventy-three articles were screened on title. Five hundred fifty-seven abstracts were assessed, and 132 publications were enrolled into the final, comprehensive full text analysis. Ultimately, 19 records met our eligibility criteria. The flowchart of study enrollment is shown in Figure 1.

Fig. 1. Study flowchart

162 Study characteristics

All publications processed data of trauma patients with suspected hemorrhage from the past 10 years. From 19 studies yielding 3057 patients in total, 13 records collected data retrospectively and 6 prospectively. The number of participants in each dataset ranged from 15 to 428. Ten studies enrolled patients only if they received blood products as a part of the initial management. Seven publications used hemodynamic instability identified mainly by vital parameters as inclusion criteria. One study analyzed patients with a positive result on FAST examination after blunt abdominal trauma. One research enrolled patients with abdominal gunshot injuries. Each of the inclusion criteria listed above entails a strong suspicion for significant bleeding. The main characteristics of the 19 eligible studies are summarized in Table 1. The more comprehensive description of the papers is available in the supplementary material (Table S2).

First author, year	Country	Data collection	Patient characteristics	Patient number	HR mean ± SD (PH/AD)	Morta ity n, (%)
Bohonek 2019 [27]	Czech Republic	retrospective	received blood products	46	94.8 ± 59.0 (AD)	10 (21.7)
Boudreau 2019 [28]	USA	retrospective	received blood products	116	101.3 ± 43.0 (PH)	27 (23.3)
Duchesne 2019 [29]	USA	retrospective	hemodynamic instability	279	120.6 ± 27.7 (AD)	89 (32.0)
Montazer 2019 [30]	Iran	prospective	hemodynamic instability	400	110.0 ± 14.0 (AD)	67 (16.7)
<i>Priestley</i> 2019 [31]	USA	retrospective	received blood products	283	104.0 ± 24.0 (PH)	88 (31.1)
Barmparas 2018 [32]	USA	retrospective	received blood products	120	101.1 ± 39.7 (AD)	59 (49.2)
Chaochan kit 2018 [33]	Thailand	retrospective	received blood products	15	113.0 ± 22.1 (AD)	12 (80.0)
Moore 2018 [34]	USA	prospective	hemodynamic instability	125	110.0 ± 15.9 (PH)	16 (12.8
Ng 2018 [35]	Canada	retrospective	hemodynamic instability	117	112.0 ± 35.0 (AD)	22 (19.0
Guo 2017 [36]	China	prospective	hemodynamic instability	428	111.3 ± 17.9 (AD)	104 (23.4
Heidari 2017 [37]	Iran	prospective	blunt abdominal trauma with positive FAST	168	105.3 ± 23.4 (AD)	57 (33.9
Luehr 2017 [38]	USA	retrospective	received blood products	115	133.3 ± 21.4 (PH)	20 (17.4
Naumann 2017 [39]	UK	retrospective	received blood products	17	108.0 ± 16.2 (AD)	3 (17.0
Savage 2017 [40]	USA	retrospective	received blood products	330	108.2 ± 55.3 (AD)	82 (24.8)
Day 2016 [41]	USA	retrospective	received blood products	116	98.0 ± 24.0 (PH)	13 (11.0
Ordoñez 2016 [42]	Colombia	retrospective	hemodynamic instability	171	112.6 ± 23.5 (AD)	26 (15.2
Shah 2015 [43]	Pakistan	retrospective	isolated abdominal gunshot wound	70	99.8 ± 30.3 (AD)	11 (15.7

Thurston	South	prospective	hemodynamic instability	50	123.3 ±	11
2015 [44]	Africa				13.1 (AD)	(22.0)
Sisak 2013	Australia	prospective	received blood products	91	100.0 ±	13
[45]			_		30.1 (AD)	(14.0)

Table 1. Baseline characteristics of the included studies. The majority of the papers enrolled trauma patients receiving blood products and/or showing signs of hemodynamic instability. Hemodynamic instability was defined by vital parameters in most cases. Most of the data was collected retrospectively. The number of participants in each dataset ranged from 15 to 428. There is a significant heterogeneity in mortality between datasets. The need for massive transfusion is accompanied by a prominently high mortality rate. A mean heart rate (HR) > 120 bpm does not entail an outstanding mortality rate. *only cohort B consisted of trauma patients with active bleeding

PH=prehospital, AD=upon admission, pRBC=packed red blood cells, RCT=randomized controlled trial, SBP=systolic blood pressure, DBP=diastolic blood pressure, MAP=mean arterial pressure, ISS=injury severity score, HR=heart rate, bpm=beats per minute, BD=base deficit, FAST=focused assessment with sonography for trauma

Study quality

The methodological quality of the enrolled papers was investigated with QUIPS tool. The domain 'Study attrition' was not suitable for the retrospective studies. In 5 prospective studies, a moderate risk for study attrition bias was identified. All papers were judged to carry a low risk of bias in 'Study participation' and 'Prognostic factor measurement' domains. In contrast, almost half of the records were accompanied by a moderate risk of bias with regards to 'Study confounding', since the role of important confounders was not clarified in these reports. The results of the QUIPS assessment are shown in Figure 2.

Fig. 2 Risk of bias assessment

Primary meta-regression

- Our primary meta-regression investigated the relation between HR and mortality in trauma patients with hemorrhage based on all 19 datasets. We found no significant relation between HR and the outcome (p=0.847); thus, a linear association could not be confirmed. The results with the regression line are demonstrated in Figure 3.
- Fig. 3 Relation between HR and mortality of bleeding trauma patients

Subgroup analysis

Due to the relative heterogeneity of the patient enrollment criteria of the individual papers, a subgroup of 10 studies utilizing the use of blood products in the initial management as inclusion criteria was formed and analyzed separately. Again, our findings demonstrated no significant relation and linear association between HR and mortality rate (Fig. 4).

Fig. 4 Subgroup analysis of studies on trauma patients who received blood products

DISCUSSION

Interpretation of results

BMJ Open

The present study was designed to investigate and update current knowledge on the relation between
HR and mortality in bleeding trauma patients. We identified 19 studies providing early HR and mortality
data on trauma patients with hemorrhage from the past 10 years through database search. Due to the
relative heterogeneity of the patient enrollment criteria of the individual papers, a subgroup of 10 records
was created. Each of these 10 studies provided data on trauma patients who received blood products.
Meta regressions were conducted on the data of all records and the subgroup, respectively.

212 No significant relation was found between HR and mortality in our meta regressions. This result supports
 213 the evidence provided by studies doubting the value of HR in the initial assessment of potentially
 214 bleeding trauma patients. Additionally, our findings raise further concerns over the validiy of HR in the
 215 ATLS classification of hypovolemic shock.

HR is an easily accessible vital parameter that indubitably reacts to circulatory volume depletion [5,6]. However, the complexity of this reaction seems to contain too many possibilities for misinterpretation to be used in the simplified scheme presented by ATLS. The current classification of hypovolemic shock suggests that HR increases continuously parallel to the severity of bleeding. The increase can stagnate between class I-II and III-IV according to ATLS.[3] This scheme seems to be incongruent with the existing literature on the physiology of HR change during intravascular volume depletion. The HR response tends to follow a biphasic or triphasic pattern instead of continuous increase [8,10,11]. If it comes to a decrease or stagnation in HR value, it is likely to occur at two separate stages of hemorrhage. First, due to increased vagal activity caused by a Bezold-Jarisch-like reflex just around 30% blood loss, [5,10] between shock classes II and III, where ATLS suggests a clear increase in HR. Secondly, at the end stage of hemorrhage, bradycardia appears preceding cardiac arrest.[15,23,24] Based on these observations, the pattern of HR alterations during hemorrhage suggested by ATLS may reflect the clinical condition more accurately after minor modifications (Table 2).

Severity classes Estimated blood loss				Class III 31-40%	Class IV >40%
	HR	\leftrightarrow	↔/↑	\uparrow	ተ/ተተ
S	HR*	\leftrightarrow	1	↔/↑	↓/↑
Physiologic variables	SBP	\leftrightarrow	\leftrightarrow	$\leftrightarrow / \downarrow$	\checkmark
c var	GCS	\leftrightarrow	\leftrightarrow	\downarrow	\checkmark
ologi	Pulse pressure	\leftrightarrow	\downarrow	\downarrow	\checkmark
hysic	Respiratory rate	\leftrightarrow	\leftrightarrow	\uparrow	\uparrow
P	Urine output	\leftrightarrow	\leftrightarrow	\downarrow	$\downarrow\downarrow$
	BD	0-2 mEq	2-6 mEq	6-10 mEq	≥10 mEq
	Transfusion	Monitor	Possible	Yes	Massive transfusion

BMJ Open

Table 2. Advanced Trauma Life Support (ATLS) classification of hypovolemic shock including
 suggested modifications in the pattern of heart rate (HR) derangements. The table is based on the 10th
 edition of ATLS. Estimated blood loss is shown as percentage of total blood volume.

*The suggested modifications are highlighted in bold: possible stagnation in HR value is indicated around 30% blood loss due to increased vagal activity. The possibility of bradycardia in profound bleeding in Class IV is highlighted

⁹ 235 HR=heart rate, SBP=systolic blood pressure, GCS=Glasgow Coma Scale, BD=base deficit

Despite criticism, HR is a promptly available vital sign that may lead physicians in the right direction in a relatively high percentage of cases when it comes to the initial management of potentially bleeding trauma patients. However, the question remains if it is effective enough to be taken into consideration when we can also rely on parameters with higher sensitivity and specificity for bleeding - such as base deficit. Multiple studies have presented the inferiority of HR as compared to other predictors included in the ATLS criteria such as systolic blood pressure (SBP), Glasgow Coma Scale (GCS) and base deficit (BD).[25,26] Based on these concerns, the role of HR in the classification of hypovolemic shock and the initial management of the severely injured should be re-evaluated.

25 244 Strenghts and limitations

245 Our study focuses on injury-related severe hemorrhage, a condition carrying high clinical importance.
246 In the previous decades, trauma care has gone through remarkable development. On that note, we
247 decided to use scientific data only from the past 10 years. The included papers were judged to carry a
248 relatively low risk of bias.

Naturally, our study also has its limitations. Although mortality is a highly objective outcome and we included patients only with significant hemorrhage, the direct cause of death may be difficult to determine in some cases. Prehospital measures may have affected the HR values registered upon admission. There is a notable difference in patient number among some of the included studies. The characteristics of the patient population by the individual records show a significant heterogeneity. To minimize this, a subgroup analysis was performed on patients who received blood products during initial in-hospital trauma care. These limitations prevented us from performing an adequate meta-analysis; however, we believe that we managed to raise attention on a clinically important issue.

47 257 Conclusions

The legitimity of HR in the initial assessment of hypovolemic shock seems to be obvious, but in fact, its
 usefulness is questionable due to unsatisfactory sensitivity and specificity. The complexity of HR
 response during hemorrhage leads to the possibility of misinterpretation, false sense of hemodynamic
 stability and consequent delay in adequate therapy.

Further research is required to reappraise HR as a physiologic variable in the ATLS classification of
 hypovolemic shock. As a reaction frequently associated with bleeding, tachycardia should raise
 suspicion for hemorrhage, but it might not be appropriate as one of the determining factors of therapeutic
 decisions, such as administration of blood products. In addition to the literature demonstrating the multi-

BMJ Open

phasic response of HR to bleeding, our study presents the lack of linear association with mortality.
Considering these, modifying the pattern of HR derangements in the ATLS shock classification may
make this pragmatic guide even more precise.

10 269 STATEMENTS

12 270 Conflict of Interests13

The authors declare that the research was conducted in the absence of any commercial or financialrelationships that could be construed as a potential conflict of interest.

273 Funding

The study was funded by the following National Research Development and Innovation Office grant: FK138839. PH was further supported by the Bolyai János Grant of the Hungarian Science Academy: BO/00605/21/5. PJ was funded by the Human Resource Development Operational Programme Grant: EFOP- 3.6.3-VEKOP-16-2017-00009. Funders did not influence the design and scientific content of our paper in any way.

27 28 279 Authors' contributions

PJ: preparation of the draft of the manuscript, contribution in study design, selection of studies, data extraction; LH: statistical analysis, interpretation of data; PH: expert in the field of internal medicine, provided revisions to the scientific content of the manuscript; EC: expert in the field of traumatology, substantial contribution in study design and interpretation of data, provided revisions to the scientific content of the manuscript; EB: data extraction, preparation of the standardized data collection sheet; TH: risk of bias assessment, stylistic and grammatical revision of the manuscript; IG: substantial contribution in study design, selection of studies, data extraction; AL: formatting the manuscript, stylistic revision of the manuscript; AS: statistical analysis, interpretation of data; ZR: risk of bias assessment, preparation of the manuscript; EP: participation in the design of the study and its coordination; JT: provided revisions to the scientific content of the manuscript, validation of data extraction; PH: study design, preparation of the manuscript, provided revisions to the scientific content of the manuscript

- 46
 47 291 Hereby, all authors certify that they have participated sufficiently in the work to take public
 48
 49 292 responsibility for the content.
- 51 293 Ethics approval and consent to participate

52 294 Not applicable.

⁵⁴ 295 Consent for publication
⁵⁵

56 296 Not applicable.

- 58 297 Availability of data and materials

BMJ Open

Our study uses published data only. The original contributions presented in the study are included in the article and supplementary material, further inquiries can be directed to the corresponding author. Patient and public involvement Patients and public were not specifically involved in designing the study. Acknowledgements There are no acknowledgements in association with the present study. REFERENCES 1. Mutschler M, Paffrath T, Wölfl C, Probst C, Nienaber U, Schipper IB, et al. The ATLS(®) classification of hypovolaemic shock: a well established teaching tool on the edge? Injury. (2014) 3:S35-8. doi: 10.1016/j.injury.2014.08.015. 2. Evans JA, van Wessem KJ, McDougall D, Lee KA, Lyons T, Balogh ZJ. Epidemiology of traumatic comprehensive population-based assessment. World J Surg. (2010) 34:158-63. deaths: https://doi.org/10.1007/s00268-009-0266-1 3. Henry S, Brasel K, Stewart RM, American College of Surgeons. "Shock". In: Henry S, Brasel K, Stewart RM, editors. Advanced trauma life support: student course manual. Chicago, IL (2018). p. 42-61. 4. Brasel KJ, Guse C, Gentilello LM, Nirula R. Heart rate: is it truly a vital sign? J Trauma (2007) 62:812-7. doi: 10.1097/TA.0b013e31803245a1 5. Secher NH and Van Lieshout JJ. Heart rate during haemorrhage: time for reappraisal. J Physiol (2010) 588:19. doi: 10.1113/jphysiol.2009.184499 6. Guyton AC. Textbook of Medical Physiology. Philadelphia (1986). 332-43 p. 7. Braunwald E, Williams GH. "Alterations in arterial pressure and the shock syndrome". In: Jameson JL, editor. Harrison's principles of internal medicine. (1987). p. 153-6. 8. Guly HR, Bouamra O, Spiers M, Dark P, Coats T, Lecky FE. Vital signs and estimated blood loss in patients with major trauma: testing the validity of the ATLS classification of hypovolaemic shock. Resuscitation. (2011) 82:556-9. doi: 10.1016/j.resuscitation.2011.01.013. 9. Victorino GP, Battistella FD, Wisner DH. Does tachycardia correlate with hypotension after trauma? J Am Coll Surg (2003) 196:679-84. doi: 10.1016/S1072-7515(03)00128-5 10. Jacobsen J and Secher NH. Heart rate during haemorrhagic shock. Clin Physiol (1992) 12:659-66. doi: 10.1111/j.1475-097x.1992.tb00369.x

BMJ Open

3	328	11. Little RA, Kirkman E, Driscoll P, Hanson J, Mackway-Joneset K. Preventable deaths after injury:
4 5	329	why are the traditional 'vital' signs poor indicators of blood loss? Journal of accident & emergency
6 7	330	medicine (1995) 12:1-14. doi: 10.1136/emj.12.1.1
8 9	331	12. Mutschler M, Nienaber U, Brockamp T, Wafaisade A, Fabian T, Paffrath T, et al. Renaissance of
10	332	base deficit for the initial assessment of trauma patients: a base deficit-based classification for
11 12	333	hypovolemic shock developed on data from 16,305 patients derived from the TraumaRegister DGU®.
13 14	334	Crit Care (2013) 17:R42. doi: 10.1186/cc12555.
15 16	335	13. Mizushima Y, Ueno M, Watanabe H, Ishikawa K, Matsuoka T. Discrepancy between heart rate and
17	336	makers of hypoperfusion is a predictor of mortality in trauma patients. J Trauma. (2011) 71:789-92. doi:
18 19 20	337	10.1097/TA.0b013e31822f7bbd0020
21	338	14. Ley EJ, Singer MB, Clond MA, Ley HC, Mirocha J, Bukur M, et al. Admission heart rate is a
22 23	339	predictor of mortality. J Trauma Acute Care Surg. (2012) 72:943-47. doi:
24 25	340	10.1097/TA.0b013e3182465527
26 27	341	15. Ageron FX, Gayet-Ageron A, Steyeberg E, Bouzat P, Roberts Ian. Prognostic model for traumatic
28	342	death due to bleeding: cross-sectional international study. BMJ Open (2019) 9:e2044-6055. doi:
29 30	343	10.1136/bmjopen-2018-026823
31 32	344	16. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewanet Y, et al. Effects of tranexamic acid
33 34	345	on death, vascular occlusive events, and blood transfusion in trauma patients with significant
35	346	haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet (2010) 376:23-32. doi:
36 37	347	10.1016/S0140-6736(10)60835-5
38	2.40	
39 40	348	17. Boling B, Moore K. Tranexamic acid (TXA) use in trauma. J Emerg Nurs (2012) 38:496-7. doi:
41	349	10.1016/j.jen.2012.06.001
42 43	350	18. Cole E, Davenport R, Willett K, Brohi K. Tranexamic acid use in severely injured civilian patients
44	351	and the effects on outcomes: a prospective cohort study. Ann Surg. (2015) 261:390-4. doi:
45 46 47	352	10.1097/SLA.0000000000000717
48	353	19. Kutcher ME, Kornblith LZ, Narayan R, Curd V, Daley AT, Redick BJ, et al. A paradigm shift in
49 50	354	trauma resuscitation: evaluation of evolving massive transfusion practices. JAMA Surg. (2013) 148:834-
51 52	355	40. doi: 10.1001/jamasurg.2013.2911
53 54	356	20. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items
55	357	for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev (2015) 4:1.
56 57	358	doi: 10.1186/2046-4053-4-1
58		
59 60		

21. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. (2013) 158:280-6. doi: 10.7326/0003-4819-158-4-201302190-22. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol (2014) 14:135. doi: 10.1186/1471-2288-14-135 23. Barriot P, Riou B. Hemorrhagic shock with paradoxical bradycardia. Intensive Care Med (1987) 13:203-7. doi: 10.1007/BF00254705 24. Hooper N. Armstrong TJ. Hemorrhagic Shock. (2020).https://www.ncbi.nlm.nih.gov/books/NBK470382/ [Accessed: February 25, 2021] 25. Perel P, Prieto-Merino D, Shakur H, Clayton T, Lecky F, Bouamra O, et al. Predicting early death in patients with traumatic bleeding: development and validation of prognostic model. BMJ (2012) 345:e5166. doi:10.1136/bmj.e5166 26. Jávor P, Csonka E, Butt E, Rárosi F, Babik B, Török L, et al. Comparison of the previous and current trauma-related shock classifications – A retrospective cohort study from a level I trauma centre. Eur Surg Res (2021) doi: 10.1159/000516102 27. Bohonek M, Kutac D, Landova L, Koranova M, Sladkova E, Staskova E, et al. The use of cryopreserved platelets in the treatment of polytraumatic patients and patients with massive bleeding. Transfusion (2019) 59:1474-78. doi: 10.1111/trf.15177 28. Boudreau RM, Deshpande KK, Day GM, Hinckley WR, Harger N, Pritts TA, et al. Prehospital Tranexamic Acid Administration During Aeromedical Transport After Injury. J Surg Res (2019) 233:132-38. doi: 10.1016/j.jss.2018.07.074 29. Duchesne J, Costantini TW, Khan M, Taub E, Rhee P, Morse B, et al. The effect of hemorrhage control adjuncts on outcome in severe pelvic fracture: A multi-institutional study. J Trauma Acute Care Surg (2019) 87:117-24. doi: 10.1097/TA.00000000002316 30. Montazer SH, Jahanian F, Khatir IG, Bozorgi F, Assadi T, Pashaei SM, et al. Prognostic Value of Cardiac Troponin I and T on Admission in Mortality of Multiple Trauma Patients Admitted to the Emergency Department: a Prospective Follow-up Study. Med Arch (2019) 73:11-14. doi: 10.5455/medarh.2019.73.11-14 31. Priestley EM, Inaba K, Byerly S, Biswas S, Wong MD, Lam L, et al. Pulse Pressure as an Early Warning of Hemorrhage in Trauma Patients. J Am Coll Surg (2019) 229(2):184-191. doi: 10.1016/j.jamcollsurg.2019.03.021

Page 15 of 25

1 2

BMJ Open

3	391	32. Barmparas G, Dhillon NK, Smith EJ, Mason R, Melo N, Thomsen GM, et al. Patterns of vasopressor
4 5	392	utilization during the resuscitation of massively transfused trauma patients. Injury (2018) 49:8-14. doi:
6 7	393	10.1016/j.injury.2017.09.021
8 9	394	33. Chaochankit W, Akaraborworn O, Sangthong B, Thongkhao K. Combination of blood lactate level
10 11	395	with assessment of blood consumption (ABC) scoring system: A more accurate predictor of massive
12 13	396	transfusion requirement. Chin J Traumatol. (2018) 21:96-9. doi: 10.1016/j.cjtee.2017.12.003
14	397	34. Moore HB, Moore EE, Chapman MP, McVaney K, Bryskiewicz G, Blechar R, et al. Plasma-first
15 16	398	resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a
17 18	399	randomised trial. Lancet (2018) 392:283-91. doi: 10.1016/S0140-6736(18)31553-8
19 20	400	35. Ng M, Perrott J, Burgess S. Evaluation of tranexamic acid in trauma patients: A retrospective
21 22	401	quantitative analysis. Am J Emerg Med. (2019) 37:444-9. doi: 10.1016/j.ajem.2018.06.010
23 24	402	36. Guo SB, Chen YX, Yu XZ. Clinical Characteristics and Current Interventions in Shock Patients in
25	403	Chinese Emergency Departments: A Multicenter Prospective Cohort Study. Chin Med J (2017)
26 27	404	130:1146-54. doi: 10.4103/0366-6999.205862
28 29	405	37. Heidari K, Taghizadeh M, Mahmoudi S, Panahi H, Shad EG, Asadollahi S. FAST for blunt
30 31	406	abdominal trauma: Correlation between positive findings and admission acid-base measurement. Am J
32 33	407	Emerg Med (2017) 35:823-9. doi: 10.1016/j.ajem.2017.01.035
34	408	38. Luehr E, Grone G, Pathak M, Austin C, Thompson S. Administration of tranexamic acid in trauma
35 36	409	patients under stricter inclusion criteria increases the treatment window for stabilization from 24 to 48
37 38	410	hours-a retrospective review. Int J Burns Trauma (2017) 7:115-9
39 40	411	39. Naumann DN, Hazeldine J, Dinsdale RJ, Bishop JR, Midwinter MJ, Harrison P, et al.
41	412	Endotheliopathy is associated with higher levels of cell-free DNA following major trauma: A
42 43 44	413	prospective observational study. PLoS One (2017) 12:e0189870. doi: 10.1371/journal.pone.0189870
44 45	414	40. Savage SA, Zarzaur BL, Brewer BL, Lim GH, Martin AC, Magnotti LJ, et al. 1: 1 Transfusion
46 47	415	strategies are right for the wrong reasons. J Trauma Acute Care Surg (2017) 82:845-52. doi:
48 49	416	10.1097/TA.00000000001402
50 51	417	41. Day DL, Anzelon KM, Conde FA. Association of Prehospital Shock Index and Trauma Bay
52	418	Uncrossmatched Red Blood Cell Transfusion With Multiple Transfusion. J Trauma Nurs (2016) 23:89-
53 54	419	95. doi: 10.1097/JTN.00000000000192
55 56	420	42. Ordonez CA, Herrera-Escobar JP, Parra MW, Rodriguez-Ossa PA, Mejia DA, Sanchez AI, et al.
57	421	Computed tomography in hemodynamically unstable severely injured blunt and penetrating trauma
58 59 60	422	patients. J Trauma Acute Care Surg (2016) 80:597-602. doi: 10.1097/TA.000000000000975

423 43. Shah AA, Rehman A, Shah SJ, Haider AH, Zogg CH, Zafar SN, et al. Abdominal gunshot wounds-a
424 comparative assessment of severity measures. J Surg Res (2015) 198:334-9. doi:
425 10.1016/j.jss.2015.03.061

426 44. Thurston B, Chowdhury S, Edu S, Nicol AJ, Navsaria PH. Time since injury is the major factor in
427 preventing tranexamic acid use in the trauma setting: An observational cohort study from a major trauma
428 centre in a middle-income country. S Afr J Surg (2015) 53:13-8. doi: 10.7196/SAJS.2250

429 45. Sisak K, Manolis M, Hardy BM, Enninghorst N, Bendinelli C, Balogh ZsJ. Acute transfusion
430 practice during trauma resuscitation: who, when, where and why? Injury (2013) 44:581-6. doi:
431 10.1016/j.injury.2012.08.031

432 FIGURE LEGENDS

Fig. 1. Study flowchart. Our search strategy resulted 2017 papers. After excluding articles published
before 2010 and duplicates, a systematic screening was performed. Ultimately, 19 studies were enrolled
to our meta-regression

436 *heart rate (HR) was not provided in mean or median, only the number of patients in ranges of HR (e.g.,
 437 100-120 bpm) was given

2 438 Fig. 2. Risk of bias assessment.

a: The figure shows the risk of bias in the 6 main domains of the Quality In Prognostic Studies (QUIPS)
assessment, in each paper. 'Study attrition' was not suitable for the retrospective studies. In 5 prospective
studies, there was a moderate risk for study attrition bias. All studies were judged to carry a low risk of
bias in 'Study participation' and 'Prognostic factor measurement' domains. 'Study confounding' was
the worst rated domain: a moderate risk appeared in almost half of the records, in which the role of
important confounders was not reported thoroughly. Based on the assessment of the 6 main domains,
the overall risk of bias was determined for each study

- $\frac{4}{5}$ 446 **b**: The summarized risk of bias is illustrated in percentages in the main domains
- 447 Fig. 3. Relation between heart rate (HR) and mortality of bleeding trauma patients. Linear association
 448 between HR and mortality could not be identified.

0 449 HR=heart rate

- 450 Fig. 4. Subgroup analysis of studies on trauma patients who received blood products. Linear association
 451 between early heart rate (HR) and mortality rate of patients could not be identified.
- ⁵⁵ 452 HR=heart rate

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

25 26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41 42

60

records identified through database search identification EMBASE: n=752 MEDLINE: n=359 records after >10 years CENTRAL: n=369 old publications Web of Science: n=537 excluded n=1544 n=2017 records after full-text articles excluded, with duplicates removed reasons: records excluded n=1373 screening reviews: n=7 based on title case reports: n=9 n=816 include >10-year-old data: n=25 records screened early HR not recorded: n=14 n=1373 records excluded HR provided only in classes*: n=28 based on mortality data not recorded: n=22 abstract full-text articles eligibility overlapping study populations: n=3 n=425 assessed for eligibility full-text could not be found: n=3 n=132 full-text not in English: n=2 n=113 studies included in included systematic review n=19


Fig. 1. PRISMA flow diagram. Our search strategy resulted 2017 papers. After excluding articles published before 2010 and duplicates, 1373 papers were screened based on title and abstract. In 79 cases the title clearly indicated non-eligible study design such as review or systematic review. Twenty-four title pointed out that the paper is a case report of a sole case. In 124 cases, the title clearly indicated non-eligible study population such as pregnant or pediatric. Five hundred sixteen titles revealed that the study is not closely related to our research topic. In 73 cases the title clearly indicated an animal experiment. Twenty-one records were excluded based on abstract due to a non-eligible study design such as review or systematic review. The abstract indicated a non-eligible study population such as pregnant or pediatric in 94 cases. In 110 cases, the abstract indicated that the study is not closely related to our research topic. Thirty-nine animal experiments were filtered out based on abstract. Eight studies did not have an English language abstract. In 112 cases, the abstract revealed that the study includes data that is more than 10 years old. Forty-one case reports with a patient number <10 were excluded based on abstract.


After excluding a total of 816 papers based on title and 425 based on abstract, 132 full-texts were assessed for eligibility. Reasons for non-inclusion of full-text articles are detailed above in the Figure. Ultimately, 19 studies were enrolled to our meta-regression


*heart rate (HR) was not provided in mean or median, only the number of patients in ranges of HR (e.g., 100-120 bpm) was given

170x105mm (300 x 300 DPI)

BMJ Open








170x123mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2021-059271 on 19 October 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.






Fig. 4. Subgroup analysis of studies on trauma patients who received blood products. Linear association between early heart rate (HR) and mortality rate of patients could not be identified. HR=heart rate

170x123mm (300 x 300 DPI)

Page 21 of 25

PRISMA 2020 Checklist


Page 21 of 25		BMJ Open	
1 PRIS	5MA 2	020 Checklist	
 3 4 Section and 5 Topic 6 	ltem #	Checklist item	Location where item is reported (Page nr.)
7 TITLE	1		
8 Title	1	Identify the report as a systematic review.	1
9 ABSTRACT	1		
10 Abstract	2	See the PRISMA 2020 for Abstracts checklist.	2
13 Rationale	3	Describe the rationale for the review in the context of existing knowledge.	2-3
14 Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	3
15 METHODS	5		4
16 Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	4
¹ 1 Information ¹⁸ sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to Hentify studies. Specify the date when each source was last searched or consulted.	4
20 Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	4
2 Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	4-5
23 Data collection 24 process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	4, 10
26 Data items 27	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	5
28 29	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	4
30 Study risk of bias 31 assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	5
32 Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	5
³³ Synthesis ³⁴ methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intergention characteristics and comparing against the planned groups for each synthesis (item #5)).	-
35 36	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	-
37 38	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	-
39 40	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	-
41	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	-
42	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	-
43 Reporting bias	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	5
44 assessment		For peer review only - http://bmiopen.bmi.com/site/about/guidelines.xhtml	
45 46 47			



PRISMA 2020 Checklist

			BMJ Open BMJ Open	Page 22 of 25
1 2	PRIS	MA 2	BMJ Open 36, bm, open 2020 Checklist	
	Section and Topic	ltem #	Checklist item	Location where item is reported (Page nr.)
-	Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	-
9	RESULTS			
10 11	Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the ramber of studies included in the review, ideally using a flow diagram.	5, Fig. 1
12		16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were executed.	-
	Study characteristics	17	Cite each included study and present its characteristics.	6 (Table 1)
IΨ	Risk of bias in studies	18	Present assessments of risk of bias for each included study.	6-7 (Fig. 2)
·Ψ	Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	7 (Fig 3-4)
	Results of	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	-
21 22	syntheses	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary esting ate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	-
23		20c	Present results of all investigations of possible causes of heterogeneity among study results.	-
24 25		20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	-
26	Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	6-7, (Fig. 2)
	Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	-
29	DISCUSSION			
30	Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	7-8
31		23b	Discuss any limitations of the evidence included in the review.	9
33		23c	Discuss any limitations of the review processes used.	9
34		23d	Discuss implications of the results for practice, policy, and future research.	9
35	OTHER INFORMA	TION	Les	
~ +	Registration and	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	4
37 38	protocol	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	4
39		24c	Describe and explain any amendments to information provided at registration or in the protocol.	-
40	Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	9
	Competing interests	26	Declare any competing interests of review authors.	9
44	Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; dage extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	10

Page 23 of 2



Study: first author, year of publication	Data origin: institute, country	Data collection: type, date	Patient characteristics	Patient number	HR mean ± SD (PH/AD)	Mortality n, (%)
Bohonek 2019	Military University Hospital Prague, Czech Republic	retrospective, single-center, 2014-2018	received blood products (fresh apheresis platelets or cryopreserved platelets)	46	94.8 ± 59.0 (AD)	10 (21.7)
Boudreau 2019	University of Cincinnati Medical Center, Cincinnati, Ohio, USA	retrospective, single-center, April 2014 – October 2015	received blood products and tranexamic acid	116	101.3 ± 43.0 (PH)	27 (23.3)
Duchesne 2019	11 level I trauma centers, 1 level II trauma center from the USA	retrospective, multi-center, January 2011 – December 2016	pelvic fracture with SBP \leq 90 mmHg and/or HR \geq 120 bpm and/or BD \geq 5 mEq	279	120.6 ± 27.7 (AD)	89 (32.0)
Montazer 2019	Imam Khomeini Hospital, Sari, Iran	prospective, single-center, March 2014 – February 2015	multiple trauma with hemodynamic instability (not defined)	400	110.0 ± 14.0 (AD)	67 (16.7)
Priestley 2019	LAC+USC Medical Center, LAC+USC blood bank database, University of Southern California, Los Angeles, CA, USA	retrospective, single-center, January 2010 – October 2014	received 3 units of pRBC in any 60- minute period within 24 hours of admission and received interventional radiology or surgery for definitive hemorrhage control	283	104.0 ± 24.0 (PH)	88 (31.1)
Barmparas 2018	Cedars-Sinai Medical Center Los Angeles, CA, USA	retrospective, single-center January 2011 – October 2016	received massive transfusion (defined as 3 units of pRBC within the first hour from admission)	120	101.1 ± 39.7 (AD)	59 (49.2)
Chaochankit 2018	Songklanagarin d Hospital, Hat Yai, Thailand	retrospective, single-center, January 2014 – December 2014	received massive transfusion, met trauma team activation criteria	15	113.0 ± 22.1 (AD)	12 (80.0)
Moore 2018	Denver Health Medical Center, Denver, CO, USA	prospective, single-center, April 2014 – March 2017	$SBP \le 70 \text{ mmHg or} \\ 71-90 \text{ mmHg with} \\ HR \ge 108 \text{ bpm} \end{cases}$	125	110.0 ± 15.9 (PH)	16 (12.8
Ng 2018	British Columbia Trauma Registry, Canada	retrospective, single-center, April 2012 – June 2015	SBP ≤ 90 mmHg and/or HR ≥ 110 bpm	117	112.0 ± 35.0 (AD)	22 (19.0
Guo 2017	33 academic hospitals in 16 Chinese	prospective, multi-center, December 2013 – April 2014	new-onset hypotension unexplained by any other cause than	428	111.3 ± 17.9 (AD)	104 (23.4

	provinces, China		hemorrhage (SBP < 90 mmHg, DBP < 60 mmHg, or MAP < 65 mmHg or decreased SBP with more than 40 mmHg from baseline in a hypertensive patient), and signs of tissue hypoperfusion (tachycardia, oliguria, mottled skin, altered mental			
Heidari 2017	4 level I trauma centers from Iran	prospective, multi-center, April 2015 – September 2015	state) blunt abdominal trauma with positive FAST	168	105.3 ± 23.4 (AD)	57 (33.9)
Luehr 2017	Mercy Hospital- Springfield, Springfield, MO, USA	retrospective, single-center, 2013 - 2016	received blood products and tranexamic acid	115	133.3 ± 21.4 (PH)	20 (17.4)
Naumann 2017	University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK	retrospective, single-center, July 2015 – January 2017	received blood products, required intensive care and had a lactate value >2 mmol/l (cohort B*)	17	108.0 ± 16.2 (AD)	3 (17.6)
Savage 2017	Indiana University School of Medicine, Indianapolis IN, USA; The University of Tennessee Health Science Center, Memphis, TN, USA	retrospective, multi-center, September 2013 – May 2015	received at least one unit of pRBC within the first 24 hours of admission	330	108.2 ± 55.3 (AD)	82 (24.8)
Day 2016	The Queen's Medical Center, Honolulu, Hawaii, USA	retrospective, single-center, September 2011 – March 2013	received at least one unit of pRBC in the first 6 hours, met trauma team activation criteria	116	98.0 ± 24.0 (PH)	13 (11.0)
Ordoñez 2016	Fundación Valle del Lili, University Hospital, Cali, Colombia	retrospective, single-center, January 2012 – December 2013	ISS > 15 with hemodynamic instability (SBP < 100 mmHg and/or HR > 100 bpm and/or the need for at least 4 units of packed red blood	171	112.6 ± 23.5 (AD)	26 (15.2)

			cells in the trauma bay)			
Shah 2015	Aga Khan University Hospital, Karachi, Pakistan	retrospective, single-center, January 2011 – December 2012	isolated abdominal gunshot wound	70	99.8 ± 30.3 (AD)	11 (15.7)
Thurston 2015	Trauma Center, Groote Schuur Hospital and Faculty of Health Sciences, University of Cape Town, South Africa	prospective, single-center, September 2013 – November 2013	SBP < 90 mmHg and/or HR >110 bpm at any time from admission to 3 hours after injury	50	123.3 ± 13.1 (AD)	11 (22.0)
Sisak 2013	John Hunter Hospital and University of Newcastle, Newcastle, NSW, Australia	prospective, single-center, January 2010 – January 2011	received blood products within the first 24 hours from admission	91	100.0 ± 30.1 (AD)	13 (14.0)

Table S2. Detailed description of the characteristics of the included studies. Most papers enrolled trauma patients receiving blood products and/or showing signs of hemodynamic instability. Hemodynamic instability was defined by vital parameters in most cases. Most of the data was collected retrospectively. The number of participants in each dataset ranged from 15 to 428. There is a significant heterogeneity in mortality between datasets. The need for massive transfusion is accompanied by a prominently high mortality rate. A mean heart rate (HR) > 120 bpm does not entail an outstanding mortality rate. *only cohort B consisted of trauma patients with active bleeding

PH=prehospital, AD=upon admission, pRBC=packed red blood cells, RCT=randomized controlled trial, SBP=systolic blood pressure, DBP=diastolic blood pressure, MAP=mean arterial pressure, ISS=injury severity score, HR=heart rate, bpm=beats per minute, BD=base deficit, FAST=focused assessment with sonography for trauma

BMJ Open

BMJ Open

THE PREDICTIVE VALUE OF TACHYCARDIA FOR MORTALITY IN TRAUMA-RELATED HEMORRHAGIC SHOCK: A SYSTEMATIC REVIEW AND META-REGRESSION

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-059271.R1
Article Type:	Original research
Date Submitted by the Author:	16-Aug-2022
Complete List of Authors:	Jávor, Péter; University of Szeged, Department of Traumatology Hanák, Lilla; Pécsi Tudományegyetem Általános Orvostudományi Kar Hegyi, Péter; Pécsi Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine Csonka, Endre; Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Department of Traumatology Butt, Edina; Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Department of Traumatology Horváth, Tamara; Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Department of Traumatology Horváth, Tamara; Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar Góg, István; Military Hospital, Department of Vascular Surgery Lukacs, Anita; University of Szeged, Department of Public Health Soós, Alexandra; Pécsi Tudományegyetem Általános Orvostudományi Kar Rumbus, Zoltán; Pécsi Tudományegyetem Általános Orvostudományi Kar, Department of Thermophysiology Pákai, Eszter; Pécsi Tudományegyetem Általános Orvostudományi Kar, Department of Thermophysiology Toldi, János; Pécsi Tudományegyetem Általános Orvostudományi Kar, Department of Anesthesiology and Intensive Care Hartmann, Petra; University of Szeged, Department of Traumatology
Primary Subject Heading :	Emergency medicine
Secondary Subject Heading:	Medical education and training
Keywords:	Trauma management < ORTHOPAEDIC & TRAUMA SURGERY, Bleeding disorders & coagulopathies < HAEMATOLOGY, ORTHOPAEDIC & TRAUMA SURGERY, ACCIDENT & EMERGENCY MEDICINE

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

Z	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
23	
24	
25	
26	
27	
27	
28	
29	
30	
31	
22	
32	
33	
34	
35	
26	
36 37 38 39	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1

2

3

THE PREDICTIVE VALUE OF TACHYCARDIA FOR MORTALITY IN TRAUMA-**RELATED HEMORRHAGIC SHOCK: A SYSTEMATIC REVIEW AND META-**REGRESSION

Péter Jávor¹, Lilla Hanák², Péter Hegyi^{2;3}, Endre Csonka¹, Edina Butt¹, Tamara Horváth⁴, István 4 5 Góg⁵, Anita Lukács⁶, Alexandra Soós², Zoltán Rumbus⁷, Eszter Pákai⁷, János Toldi⁸, Petra

Hartmann^{1*} 6

- 7 ¹Department of Traumatology, University of Szeged, Szeged, Hungary
- 8 ² Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
- 9 ³Center for Translational Medicine, Department of Medicine, University of Szeged, Szeged, Hungary
- 10 ⁴Institute of Surgical Research, University of Szeged, Szeged, Hungary
- 11 ⁵ Department of Vascular Surgery, Hungarian Defense Forces Medical Center - Military Hospital, 12 Budapest, Hungary
- ⁶ Department of Public Health, Faculty of Medicine, University of Szeged, Szeged, Hungary 13
- ⁷ Department of Thermophysiology, Medical School, University of Pécs, Pécs, Hungary 14
- ⁸ Department of Anesthesiology and Intensive Care, Medical School, University of Pécs, Pécs, 15 iez oni
- 16 Hungary

22

17 *Correspondence

- 18 Petra Hartmann M.D., Ph.D.
- Semmelweis utca 6., Szeged, 6725 Hungary 19
- Tel: +(36-62) 545-531; Fax: +(36-62) 545-530 20
- 21 E-mail: hartmann.petra@med.u-szeged.hu
- 23 Word count (excluding title page, abstract, references, figures, and tables): 3101
- 24 Number of Tables: 2
- Number of Figures: 4 25

1 2		
2 3 4	26	ABSTRACT
5	27	Objectives: Heart rate (HR) is one of the physiologic variables in the early assessment of trauma-related
6 7	28	hemorrhagic shock, according to Advanced Trauma Life Support (ATLS). However, its efficiency as
8 9	29	predictor of mortality is contradicted by several studies. Furthermore, the linear association between HR
10	30	and the severity of shock and blood loss presented by ATLS is doubtful. This systematic review aims to
11 12	31	update current knowledge on the role of HR in the initial hemodynamic assessment of trauma patients.
13 14	32	Design: The present study is a systematic review and meta-regression that follows the Preferred
14 15	33	Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations.
16 17	34	Data sources: EMBASE, MEDLINE, CENTRAL and Web of Science databases were systematically
18	35	searched through on 1-September-2020.
19 20	36	Eligibility criteria: Papers providing early HR and mortality data on bleeding trauma patients were
21	37	included. Patient cohorts were considered hemorrhagic if the inclusion criteria of the studies contained
22 23	38	transfusion and/or positive focused assessment with sonography for trauma (FAST) and/or post-injury
24 25	39	hemodynamical instability and/or abdominal gunshot injury. Studies on burns, traumatic spinal or- brain
26	40	injuries were excluded. Papers published before January 2010 were not considered.
27 28	41	Data extraction and synthesis: Data extraction and risk of bias were assessed by 2 independent
29	42	investigators. The association between HR and mortality of trauma patients was assessed using meta-
30 31	43	regression analysis. As subgroup analysis, meta-regression was performed on patients who received
32 33	44	blood products.
34	45	Results: From a total of 2017 papers, 19 studies met our eligibility criteria. Our primary meta-regression
35 36	46	did not find a significant relation (p=0.847) between HR and mortality in trauma patients with
37	47	hemorrhage. Our subgroup analysis included 10 studies, and it could not reveal a linear association
38 39	48	between HR and mortality rate.
40 41	49	Conclusions: In accordance with the literature demonstrating the multi-phasic response of HR to
41 42	50	bleeding, our study presents the lack of linear association between post-injury HR and mortality.
43 44	51	Modifying the pattern of HR-derangements in the ATLS shock classification may result in a more
45	52	precise teaching tool for young clinicians.
46 47	53	Keywords: "tachycardia"; "heart rate"; "hemorrhagic shock"; "multiple trauma"; "ATLS"
48 49		
50 51	54	STRENGTHS AND LIMITATIONS OF THIS STUDY
52	55	• The paper provides a systematic search of EMBASE, MEDLINE (via PubMed), Cochrane
53 54	56	Controlled Register of Trials (CENTRAL) and Web of Science databases, utilizes rigorous
55 56	57	study selection criteria, assesses each enrolled paper for bias, and performs meta-regression
57	58	analyses.
58 59		
60		

- Studies focusing on special populations including pregnant, pediatric (<18 years of age), geriatric (≥55 years), burned and traumatic spinal- or brain injured patients were excluded from the study.
 - The heterogeneity and the difference in patient number among the included studies prevented us from performing an adequate meta-analysis.
 - Although mortality is a highly objective outcome, the fact that in some cases hemorrhage might not been the direct cause of death even if bleeding was present is an important limitation of the study.

INTRODUCTION

Hypovolemia caused by hemorrhage is the most common cause of shock in trauma. Delay in the recognition of shock has been linked to unfavorable outcomes such as organ dysfuntion and mortality.[1,2] The initial assessment of trauma-related hypovolemic shock is based on derangements of physiologic variables according to the recommendations of Advanced Trauma Life Support (ATLS).[3] Among these variables, heart rate (HR) is one of the most controversial when it comes to blood loss.[4-7] As commonly criticized, HR is not only influenced by hemodynamic changes, but also by several other factors such as anxiety, pain, and medications resulting in a low specificity for hemorrhage.[4,8,9] Furthermore, ATLS suggests the continuously increasing tendency of HR in accordance with the severity of bleeding.[3] However, in clinical reality, the HR response to hemorrhage is rather biphasic or triphasic than linear.[8,10,11] Consequently, the utility of HR in the early management of bleeding trauma patients was called into doubt during the past decades.[4,5,8,9]

The reliability of HR was already questioned in the early 2000s by a retrospective analysis on 14325 trauma patients. According to the results of this study, HR displayed insufficient sensitivity and specificity in predicting hypotension after trauma.[9] A few years later, a registry analysis denoted further doubts in HR, as it had performed poorly in predicting the need for an emergent intervention and administration of packed red blood cells (pRBC) in the first 24 hours post-injury.[4] Additionally, as ATLS was progressively widespread, the role of HR in the classification of hypovolemic shock sparked controversy. In 2013, 16305 patients from the German trauma register (DGU®) were allocated into shock severity classes (I-IV) according to ATLS guidance.[12] Ultimately, no group displayed relevant tachycardia at all. According to these data, expecting tachycardia in case of hypovolemia can be misleading in many instances. Moreover, a false sense of hemodynamic stability based on normal HR can lead to fatal consequences, since the lack of tachycardia in hypoperfusion is associated with poor prognosis.[13]

91 Despite criticism, increased HR has been known as a characteristic of hypovolemic shock for a very
92 long time. The utility of HR as a predictor of mortality is supported by several papers.[14,15] An
93 international, cross-sectional study using data from two large trauma cohorts was conducted to develop

Page 5 of 28

BMJ Open

and va	94
relatio	95
A nota	96
makes	97
one of	98
of tran	99
The pr	100
with h	101
contra	102
loss pr	103
shift ir	104
knowl	105
compr	106
regress	107
the sev	108
dysfun	109
HR in	110
MATI	111
Protoc	112
The pr	113
and M	114
inform	115
system	116
A syst	117
(CEN]	118
search	119
search sign" (119 120

lidate a prognostic model to predict death due to bleeding. Although HR showed a significant n to mortality, the curve was U-shaped as opposed to the linear model presented by ATLS.[15]

ble limitation of previous studies is that trauma protocols have undergone several changes, which

recent information incomparable with data from the past. In 2010, the CRASH-2 trial brought

the most prominent findings of the past decades with the validation of the safeness and effectivity examic acid (TXA).[16-18]

resent systematic review investigates the role of HR in the initial assessment of trauma patients nemorrhage. Regarding the efficiency of HR as a predictor of outcome in trauma, there is dictory data in the literature. [4,5,15] Furthermore, the linear association between HR and blood esented by ATLS is questionable.[8,15] Due to the development of trauma care and a paradigm n the initial fluid resuscitation approach in the past decades, [16,19] we aimed to update current edge on the effectivity of HR as predictor of mortality post-injury. For this purpose, a ehensive database search has been conducted, data has been extracted and analyzed through metasions. As a primary outcome, the relationship between HR and mortality has been assessed. Since verity of bleeding has a close relation to the risk for adverse outcomes including increased organ action and mortality, our study may be able to initiate further research reappraising the validity of the ATLS classification of hypovolemic shock.

ERIALS AND METHODS

col and search strategy

resent review is reported in accordance with Preferred Reporting Items for Systematic Reviews eta-Analyses (PRISMA).[20] The PRISMA checklist for our work is available in the supporting ation (Table S1). The review protocol was registered in the Open Science Framework (OSF) under registration DOI: 10.17605/OSF.IO/HJWYR.

ematic search of EMBASE, MEDLINE (via PubMed), Cochrane Controlled Register of Trials **FRAL**) and Web of Science databases was performed on 1 September 2020 with the following terms: "trauma" AND ("heart rate" OR "pulse rate" OR "tachycardia" OR "bradycardia" OR "vital OR "vital signs" OR "vital parameter" OR "vital parameters") AND "mortality" AND ("bleeding" aemorrhage" OR "hemorrhage" OR "haemodynamic" OR "hemodynamic"). Articles published before 2010 were excluded from our study.

Eligibility criteria

Records on bleeding trauma patients were considered for eligibility only if they provided initial HR values (prehospital (PH) or upon admission (AD)) in addition to mortality data covering a time interval not exceeding 30 days from the time of injury. Only full-text articles were considered. Non-English language reports, reviews, conference abstracts and case reports with low patient number (<10) were excluded. Taking the development of trauma care in the past decade into consideration (e.g.: introduction 129 of TXA,[16] and paradigm shift in fluid resuscitation [19]) all studies that included data on patients
 130 treated before 2010 were also excluded.

To consider a patient cohort hemorrhagic, the inclusion criteria of the individual studies had to include transfusion of blood products and/or positive focused assessment with sonography for trauma (FAST) examination and/or hemodynamical instability after trauma and/or abdominal gunshot injury. Records on special populations such as pregnant, pediatric (<18 years of age) or geriatric (≥55 years) were not considered. Studies on patients suffering burns, traumatic spinal or- brain injuries were excluded.

With excluding special populations and pediatric and older age groups we aimed to reduce the influence
of confounding factors. Since studies of geriatric trauma patients have used age cutoffs ranging from 55
to 80 years and there is no clear consensus in the literature,[21,22] we decided to exclude study
populations of 55 years of age or older to diminish the effects of age-related confounding factors.

140 Study selection

After having duplicates removed with the help of a reference manager software (EndNote X7), articles published before 2010 were also discarded. On the remaining studies, title and abstract screenings were performed by two review authors (PJ, IG). Thereafter, the full texts of the potentially eligible records were obtained and assessed based on the criteria described above. Disagreements were resolved by consensus.

32 146 Data extraction

The following information was extracted from the eligible studies: title, first author's name, year of publication, study design, data origin (country, hospital database/registry), data collection period, inclusion criteria, subgroups, patient number of the subgroups, total patient number, HR (mean ± standard deviation (SD) or median [interquartile range] (IQR)), phase of recording HR values (PH/AD), mortality within 30 days (n, %). In case of studies using overlapping data, the less comprehensive report with the smaller sample size was excluded.

44 153 Risk of bias assessment

Quality In Prognostic Studies (QUIPS) tool was used separately by two authors (TH and ZR) to assess the risk of bias for each study.[23] Disagreements were resolved by consensus. QUIPS consists of six main domains: 'Study attrition', 'Study participation', 'Prognostic factor', 'Outcome measurement', 'Study confounding' and 'Statistical analysis and reporting'. A rating for each domain was assigned as carrying 'low', 'moderate' or 'high' risk of bias. Based on the ratings of the individual domains, the overall risk of bias was evaluated by each study.

55 56 160 Statistical analysis

57 161 The association between HR and mortality of trauma patients was assessed using meta-regression
58 162 analysis. A result of p<0.05 was considered as significant. As a subgroup analysis, meta-regression was
60 163 performed on trauma patients who received blood products. Statistical analyses were performed with

164 Stata 16 (Stata Corp, College Station, TX, USA). To convert median values to means, we used the 165 method of Xiang Wan.[24]

166 Patient and public involvement

167 Patients and public were not specifically involved in designing the study.

¹³ 168 **RESULTS**

15169 Results of systematic search and selection

Two thousand and seventeen records were identified through our search strategy on 1 September 2020. One thousand three hundred seventy-three articles were screened on title. Five hundred fifty-seven abstracts were assessed, and 132 publications were enrolled into the final, comprehensive full text analysis. Ultimately, 19 records met our eligibility criteria. The flowchart of study enrollment is shown in Figure 1.

26 175 Fig. 1. PRISMA flow diagram

28 176 Study characteristics

All publications processed data of trauma patients with suspected hemorrhage from the past 10 years. From 19 studies yielding 3057 patients in total, 13 records collected data retrospectively and 6 prospectively. The number of participants in each dataset ranged from 15 to 428. Ten studies enrolled patients only if they received blood products as a part of the initial management. Seven publications used hemodynamic instability identified mainly by vital parameters as inclusion criteria. One study analyzed patients with a positive result on FAST examination after blunt abdominal trauma. One research enrolled patients with abdominal gunshot injuries. Each of the inclusion criteria listed above entails a strong suspicion for significant bleeding. The main characteristics of the 19 eligible studies are summarized in Table 1. The more comprehensive description of the papers is available in the supplementary material (Table S2).

First author, year	Country	Data collection	Patient characteristics	Patient number	HR mean ± SD (PH/AD)	Mortal ity n, (%)
Bohonek	Czech	retrospective	received blood products	46	$94.8 \pm$	10
2019 [25]	Republic				59.0 (AD)	(21.7)
Boudreau	USA	retrospective	received blood products	116	101.3 ±	27
2019 [26]					43.0 (PH)	(23.3)
Duchesne	USA	retrospective	hemodynamic instability	279	$120.6 \pm$	89
2019 [27]					27.7 (AD)	(32.0)
Montazer	Iran	prospective	hemodynamic instability	400	$110.0 \pm$	67
2019 [28]					14.0 (AD)	(16.7)
Priestley	USA	retrospective	received blood products	283	104.0 ±	88
2019 [29]					24.0 (PH)	(31.1)

D	TIC (120	101.1	50
Barmparas 2018 [30]	USA	retrospective	received blood products	120	101.1 ± 39.7 (AD)	59 (49.2)
Chaochan	Thailand	retrospective	received blood products	15	113.0 ±	12
kit 2018 [31]			-		22.1 (AD)	(80.0)
Moore	USA	prospective	hemodynamic instability	125	$110.0 \pm$	16
2018 [32]					15.9 (PH)	(12.8)
Ng 2018	Canada	retrospective	hemodynamic instability	117	$112.0 \pm$	22
[33]					35.0 (AD)	(19.0)
Guo	China	prospective	hemodynamic instability	428	$111.3 \pm$	104
2017 [34]					17.9 (AD)	(23.4)
Heidari	Iran	prospective	blunt abdominal trauma	168	$105.3 \pm$	57
2017 [35]			with positive FAST		23.4 (AD)	(33.9)
Luehr	USA	retrospective	received blood products	115	133.3 ±	20
2017 [36]					21.4 (PH)	(17.4)
Naumann	UK	retrospective	received blood products	17	$108.0 \pm$	3 (17.6)
2017 [37]					16.2 (AD)	
Savage	USA	retrospective	received blood products	330	$108.2 \pm$	82
2017 [38]					55.3 (AD)	(24.8)
Day	USA	retrospective	received blood products	116	98.0±	13
2016 [39]					24.0 (PH)	(11.0)
Ordoñez	Colombia	retrospective	hemodynamic instability	171	$112.6 \pm$	26
2016 [40]					23.5 (AD)	(15.2)
Shah	Pakistan	retrospective	isolated abdominal	70	$99.8~\pm$	11
2015 [41]			gunshot wound		30.3 (AD)	(15.7)
Thurston	South	prospective	hemodynamic instability	50	123.3 ±	11
2015 [42]	Africa				13.1 (AD)	(22.0)
Sisak 2013	Australia	prospective	received blood products	91	100.0 ±	13
[43]					30.1 (AD)	(14.0)

Table 1. Baseline characteristics of the included studies. The majority of the papers enrolled trauma patients who received blood products (italics) and/or showed signs of hemodynamic instability. Hemodynamic instability was defined by vital parameters in most cases. Most of the data was collected retrospectively. The number of participants in each dataset ranged from 15 to 428. There was a significant heterogeneity in mortality between datasets. The need for massive transfusion was accompanied by a prominently high mortality rate. A mean heart rate (HR) > 120 bpm did not entail an outstanding mortality rate.

41 194 *only cohort B consisted of trauma patients with active bleeding

PH=prehospital, AD=upon admission, FAST=focused assessment with sonography for trauma
 PH=prehospital, AD=upon admission, FAST=focused assessment with sonography for trauma

44 196 Study quality

The methodological quality of the enrolled papers was investigated with QUIPS tool. The domain 'Study attrition' was not suitable for the retrospective studies. In 5 prospective studies, a moderate risk for study attrition bias was identified. All papers were judged to carry a low risk of bias in 'Study participation' and 'Prognostic factor measurement' domains. In contrast, almost half of the records were accompanied by a moderate risk of bias with regards to 'Study confounding', since the role of important confounders was not clarified in these reports. The results of the QUIPS assessment are shown in Figure 2.

56 203 Fig. 2 Risk of bias assessment57

204 Primary meta-regression

BMJ Open

10 209 Fig. 3 Relation between HR and mortality of bleeding trauma patients

1213210 Subgroup analysis

Due to the relative heterogeneity of the patient enrollment criteria of the individual papers, a subgroup
 of 10 studies utilizing the use of blood products in the initial management as inclusion criteria was
 formed and analyzed separately. Again, our findings demonstrated no significant relation and linear
 association between HR and mortality rate (Fig. 4).

21 215 Fig. 4 Subgroup analysis of studies on trauma patients who received blood products

25 216 DISCUSSION

217 Interpretation of results

The present study was designed to investigate and update current knowledge on the relation between HR and mortality in bleeding trauma patients. We identified 19 studies providing early HR and mortality data on trauma patients with hemorrhage from the past 10 years through database search. Due to the relative heterogeneity of the patient enrollment criteria of the individual papers, a subgroup of 10 records was created. Each of these 10 studies provided data on trauma patients who received blood products. Meta regressions were conducted on the data of all records and the subgroup, respectively.

No significant relation was found between HR and mortality in our meta regressions. This result supports
 the evidence provided by studies doubting the value of HR in the initial assessment of potentially
 bleeding trauma patients. Additionally, our findings raise further concerns over the validiy of HR in the
 ATLS classification of hypovolemic shock.

HR is an easily accessible vital parameter that indubitably reacts to circulatory volume depletion [5,6]. However, the complexity of this reaction seems to contain too many possibilities for misinterpretation to be used in the simplified scheme presented by ATLS. The current classification of hypovolemic shock suggests that HR increases continuously parallel to the severity of bleeding. The increase can stagnate between class I-II and III-IV according to ATLS.[3] This scheme seems to be incongruent with the existing literature on the physiology of HR change during intravascular volume depletion. The HR response tends to follow a biphasic or triphasic pattern instead of continuous increase [8,10,11]. If it comes to a decrease or stagnation in HR value, it is likely to occur at two separate stages of hemorrhage. First, due to increased vagal activity caused by a Bezold-Jarisch-like reflex just around 30% blood loss, [5,10] between shock classes II and III, where ATLS suggests a clear increase in HR. Secondly, at the end stage of hemorrhage, bradycardia appears preceding cardiac arrest.[15,44,45] Based on these

observations, the pattern of HR alterations during hemorrhage suggested by ATLS may reflect theclinical condition more accurately after minor modifications (Table 2).

Severity classes Estimated blood loss		Class I <15%	Class II 15-30%	Class III 31-40%	Class IV >40%	
	HR	\leftrightarrow	$\leftrightarrow / \uparrow$	\uparrow	个/个个	
S	HR*	\leftrightarrow	1	↔/↑	↓/↑	
iable	SBP	\leftrightarrow	\leftrightarrow	$\leftrightarrow / \downarrow$	\checkmark	
c var	GCS	\leftrightarrow	\leftrightarrow	\downarrow	\checkmark	
Physiologic variables	Pulse pressure	\leftrightarrow	\checkmark	\downarrow	\checkmark	
hysic	Respiratory rate	\leftrightarrow	\leftrightarrow	\uparrow	\uparrow	
Ы	Urine output	\leftrightarrow	\leftrightarrow	\downarrow	$\downarrow\downarrow$	
	BD	0-2 mEq	2-6 mEq	6-10 mEq	≥10 mEq	
Transfusion		Monitor	Possible	Yes	Massive transfusion	

Table 2. Advanced Trauma Life Support (ATLS) classification of hypovolemic shock including
suggested modifications in the pattern of heart rate (HR) derangements. The table is based on the 10th
edition of ATLS. Estimated blood loss is shown as percentage of total blood volume.

*The suggested modifications are highlighted in bold: possible stagnation in HR value is indicated
around 30% blood loss due to increased vagal activity. The possibility of bradycardia in profound
bleeding in Class IV is highlighted

247 HR=heart rate, SBP=systolic blood pressure, GCS=Glasgow Coma Scale, BD=base deficit

Despite criticism, HR is a promptly available vital sign that may lead physicians in the right direction in a relatively high percentage of cases when it comes to the initial management of potentially bleeding trauma patients. However, the question remains if it is effective enough to be taken into consideration when we can also rely on parameters with higher sensitivity and specificity for bleeding – such as base deficit. Multiple studies have presented the inferiority of HR as compared to other predictors included in the ATLS criteria such as systolic blood pressure (SBP), Glasgow Coma Scale (GCS) and base deficit (BD).[46,47] Based on these concerns, the role of HR in the classification of hypovolemic shock and the initial management of the severely injured should be re-evaluated.

- ¹⁰ 256 Strenghts and limitations
- Our study focuses on injury-related severe hemorrhage, a condition carrying high clinical importance.
 In the previous decades, trauma care has gone through remarkable development. On that note, we
 decided to use scientific data only from January 2010 September 2020 (date of database search). The
 included papers were judged to carry a relatively low risk of bias.
- Naturally, our study also has its limitations. Although mortality is a highly objective outcome and we
 included patients only with significant hemorrhage, the direct cause of death may be difficult to
 determine in some cases. Although studies on special populations have been excluded from our analysis,

it is important to emphasize that the presence of potential confounding factors affecting HR values could not be ruled out completely. Prehospital measures may have affected the HR values registered upon admission. There is a notable difference in patient number among some of the included studies. The characteristics of the patient population by the individual records show a significant heterogeneity. To minimize this, a subgroup analysis was performed on patients who received blood products during initial in-hospital trauma care. These limitations prevented us from performing an adequate meta-analysis; however, we believe that we managed to raise attention on a clinically important issue.

Conclusions

- The legitimity of HR in the initial assessment of hypovolemic shock seems to be obvious, but in fact, its usefulness is questionable due to unsatisfactory sensitivity and specificity. The complexity of HR response during hemorrhage leads to the possibility of misinterpretation, false sense of hemodynamic stability and consequent delay in adequate therapy.
- Further research is required to reappraise HR as a physiologic variable in the ATLS classification of hypovolemic shock. As a reaction frequently associated with bleeding, tachycardia should raise suspicion for hemorrhage, but it might not be appropriate as one of the determining factors of therapeutic decisions, such as administration of blood products. In addition to the literature demonstrating the multi-phasic response of HR to bleeding, our study presents the lack of linear association with mortality. Considering these, modifying the pattern of HR derangements in the ATLS shock classification may make this pragmatic guide even more precise.

LIST OF ABBREVIATIONS

- iezoni CENTRAL - Cochrane Controlled Register of Trials
- ATLS - Advanced Trauma Life Support
- HR - heart rate
- pRBC - packed red blood cells
- TXA tranexamic acid
- PRISMA - Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- PH - prehospital
- AD - on admission
- FAST - focused assessment with sonography for trauma
- SD - standard deviation
- IQR - interquartile range
- **QUIPS - Quality In Prognostic Studies**
- SBP- systolic blood pressure
- GCS Glasgow Coma Scale

BD - base deficit

299 STATEMENTS

300 Conflict of Interests

The authors declare that the research was conducted in the absence of any commercial or financialrelationships that could be construed as a potential conflict of interest.

303 Funding

The study was funded by the following National Research Development and Innovation Office grants:
FK138839; EFOP- 3.6.3-VEKOP-16-2017-00009. PHa was further supported by the Bolyai János Grant
of the Hungarian Science Academy: BO/00605/21/5. Funders did not influence the design and scientific
content of our paper in any way.

23 308 Authors' contributions

PJ: preparation of the draft of the manuscript, contribution in study design, selection of studies, data extraction; LH: statistical analysis, interpretation of data; PHe: expert in the field of internal medicine, provided revisions to the scientific content of the manuscript; EC: expert in the field of traumatology, substantial contribution in study design and interpretation of data, provided revisions to the scientific content of the manuscript; EB: data extraction, preparation of the standardized data collection sheet; TH: risk of bias assessment, stylistic and grammatical revision of the manuscript; IG: substantial contribution in study design, selection of studies, data extraction; AL: formatting the manuscript, stylistic revision of the manuscript; AS: statistical analysis, interpretation of data; ZR: risk of bias assessment, preparation of the manuscript; EP: participation in the design of the study and its coordination; JT: provided revisions to the scientific content of the manuscript, validation of data extraction; PHa: study design, preparation of the manuscript, provided revisions to the scientific content of the manuscript

42 320 Hereby, all authors certify that they have participated sufficiently in the work to take public
43 321 responsibility for the content.

- 4546 322 Ethics approval and consent to participate
- 47 323 Not applicable.
- 4950 324 Consent for publication
- 51 325 Not applicable.
- ⁵³ 326 Availability of data and materials

S27 Our study uses published data only. The original contributions presented in the study are included in the article and supplementary material, further inquiries can be directed to the corresponding author.

- 59 329 Acknowledgements
- ⁶⁰ 330 There are no acknowledgements in association with the present study.

1 2		
3	331	REFERENCES
4 5 6	332	1. Mutschler M, Paffrath T, Wölfl C, Probst C, Nienaber U, Schipper IB, et al. The ATLS(®)
7	333	classification of hypovolaemic shock: a well established teaching tool on the edge? Injury. (2014) 3:S35-
8 9	334	8. doi: 10.1016/j.injury.2014.08.015.
10	335	2. Evans JA, van Wessem KJ, McDougall D, Lee KA, Lyons T, Balogh ZJ. Epidemiology of traumatic
11 12	336	deaths: comprehensive population-based assessment. World J Surg. (2010) 34:158-63.
13		
14 15	337	https://doi.org/10.1007/s00268-009-0266-1
16 17	338	3. Henry S, Brasel K, Stewart RM, American College of Surgeons. "Shock". In: Henry S, Brasel K,
18	339	Stewart RM, editors. Advanced trauma life support: student course manual. Chicago, IL (2018). p. 42-
19 20	340	61.
21 22	341	4. Brasel KJ, Guse C, Gentilello LM, Nirula R. Heart rate: is it truly a vital sign? J Trauma (2007)
23 24	342	62:812-7. doi: 10.1097/TA.0b013e31803245a1
25 26	343	5. Secher NH and Van Lieshout JJ. Heart rate during haemorrhage: time for reappraisal. J Physiol (2010)
27	344	588:19. doi: 10.1113/jphysiol.2009.184499
28 29 30	345	6. Guyton AC. Textbook of Medical Physiology. Philadelphia (1986). 332-43 p.
31 32	346	7. Braunwald E, Williams GH. "Alterations in arterial pressure and the shock syndrome". In: Jameson
33 34	347	JL, editor. Harrison's principles of internal medicine. (1987). p. 153-6.
35 36	348	8. Guly HR, Bouamra O, Spiers M, Dark P, Coats T, Lecky FE. Vital signs and estimated blood loss in
37	349	patients with major trauma: testing the validity of the ATLS classification of hypovolaemic shock.
38 39	350	Resuscitation. (2011) 82:556-9. doi: 10.1016/j.resuscitation.2011.01.013.
40 41	351	9. Victorino GP, Battistella FD, Wisner DH. Does tachycardia correlate with hypotension after trauma?
42 43	352	J Am Coll Surg (2003) 196:679-84. doi: 10.1016/S1072-7515(03)00128-5
44 45	353	10. Jacobsen J and Secher NH. Heart rate during haemorrhagic shock. Clin Physiol (1992) 12:659-66.
46	354	doi: 10.1111/j.1475-097x.1992.tb00369.x
47 48	355	11. Little RA, Kirkman E, Driscoll P, Hanson J, Mackway-Joneset K. Preventable deaths after injury:
49 50	356	why are the traditional 'vital' signs poor indicators of blood loss? Journal of accident & emergency
51		
52 53	357	medicine (1995) 12:1-14. doi: 10.1136/emj.12.1.1
54	358	12. Mutschler M, Nienaber U, Brockamp T, Wafaisade A, Fabian T, Paffrath T, et al. Renaissance of
55 56	359	base deficit for the initial assessment of trauma patients: a base deficit-based classification for
57	360	hypovolemic shock developed on data from 16,305 patients derived from the TraumaRegister DGU®.
58 59	361	Crit Care (2013) 17:R42. doi: 10.1186/cc12555.
60		

362 13. Mizushima Y, Ueno M, Watanabe H, Ishikawa K, Matsuoka T. Discrepancy between heart rate and
 363 makers of hypoperfusion is a predictor of mortality in trauma patients. J Trauma. (2011) 71:789-92. doi:
 364 10.1097/TA.0b013e31822f7bbd0020

1 2

13

25

29

40

49

60

8 365 14. Ley EJ, Singer MB, Clond MA, Ley HC, Mirocha J, Bukur M, et al. Admission heart rate is a 9 10 366 predictor of mortality. J Trauma Acute Care Surg. (2012)72:943-47. doi: 11 367 10.1097/TA.0b013e3182465527 12

14 368 15. Ageron FX, Gayet-Ageron A, Steyeberg E, Bouzat P, Roberts Ian. Prognostic model for traumatic
15 369 death due to bleeding: cross-sectional international study. BMJ Open (2019) 9:e2044-6055. doi:
17 370 10.1136/bmjopen-2018-026823

19
371 16. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewanet Y, et al. Effects of tranexamic acid
372 on death, vascular occlusive events, and blood transfusion in trauma patients with significant
arandomised, placebo-controlled trial. Lancet (2010) 376:23-32. doi:
374 10.1016/S0140-6736(10)60835-5

²⁶
²⁷
²⁷
³⁷⁵
³⁷⁵
^{17.} Boling B, Moore K. Tranexamic acid (TXA) use in trauma. J Emerg Nurs (2012) 38:496-7. doi:
³⁷⁶
^{10.1016/j.jen.2012.06.001}

30 377 18. Cole E, Davenport R, Willett K, Brohi K. Tranexamic acid use in severely injured civilian patients
 378 and the effects on outcomes: a prospective cohort study. Ann Surg. (2015) 261:390-4. doi:
 379 10.1097/SLA.00000000000717

35
 380 19. Kutcher ME, Kornblith LZ, Narayan R, Curd V, Daley AT, Redick BJ, et al. A paradigm shift in
 37
 381 trauma resuscitation: evaluation of evolving massive transfusion practices. JAMA Surg. (2013) 148:834 382 40. doi: 10.1001/jamasurg.2013.2911

41 383 20. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items
42 384 for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev (2015) 4:1.
44 385 doi: 10.1186/2046-4053-4-1

46 47
48
386
47 21. McGwin Jr G, MacLennan PA, Fife JB, Davis GG, Rue LW. Preexisting conditions and mortality 48 in older trauma patients. J Trauma (2004) 56:1291-6. doi: 10.1097/01.ta.0000089354.02065.d0

388 22. Meldon SW, Reilly M, Drew BL, Manusco C., Fallon W. Trauma in the very elderly: a
389 community-based study of outcomes at trauma and nontrauma centers. J Trauma (2002) 52:79-84. doi:
390 10.1097/00005373-200201000-00014

391 23. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of
 392 prognostic factors. Ann Intern Med. (2013) 158:280-6. doi: 10.7326/0003-4819-158-4-201302190 393 00009

394 24. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample
395 size, median, range and/or interquartile range. BMC Med Res Methodol (2014) 14:135. doi:
396 10.1186/1471-2288-14-135

397 25. Bohonek M, Kutac D, Landova L, Koranova M, Sladkova E, Staskova E, et al. The use of
 o 398 cryopreserved platelets in the treatment of polytraumatic patients and patients with massive bleeding.
 1 399 Transfusion (2019) 59:1474-78. doi: 10.1111/trf.15177

400 26. Boudreau RM, Deshpande KK, Day GM, Hinckley WR, Harger N, Pritts TA, et al. Prehospital
401 Tranexamic Acid Administration During Aeromedical Transport After Injury. J Surg Res (2019)
402 233:132-38. doi: 10.1016/j.jss.2018.07.074

403 27. Duchesne J, Costantini TW, Khan M, Taub E, Rhee P, Morse B, et al. The effect of hemorrhage
404 control adjuncts on outcome in severe pelvic fracture: A multi-institutional study. J Trauma Acute Care
405 Surg (2019) 87:117-24. doi: 10.1097/TA.0000000002316

406 28. Montazer SH, Jahanian F, Khatir IG, Bozorgi F, Assadi T, Pashaei SM, et al. Prognostic Value of
407 Cardiac Troponin I and T on Admission in Mortality of Multiple Trauma Patients Admitted to the
408 Emergency Department: a Prospective Follow-up Study. Med Arch (2019) 73:11-14. doi:
409 10.5455/medarh.2019.73.11-14

- 410 29. Priestley EM, Inaba K, Byerly S, Biswas S, Wong MD, Lam L, et al. Pulse Pressure as an Early
 411 Warning of Hemorrhage in Trauma Patients. J Am Coll Surg (2019) 229(2):184-191. doi:
 412 10.1016/j.jamcollsurg.2019.03.021
- 37 413 30. Barmparas G, Dhillon NK, Smith EJ, Mason R, Melo N, Thomsen GM, et al. Patterns of vasopressor
 39 414 utilization during the resuscitation of massively transfused trauma patients. Injury (2018) 49:8-14. doi:
 40 415 10.1016/j.injury.2017.09.021
- 42
 416 31. Chaochankit W, Akaraborworn O, Sangthong B, Thongkhao K. Combination of blood lactate level
 44
 417 with assessment of blood consumption (ABC) scoring system: A more accurate predictor of massive
 418 transfusion requirement. Chin J Traumatol. (2018) 21:96-9. doi: 10.1016/j.cjtee.2017.12.003
- 48 419 32. Moore HB, Moore EE, Chapman MP, McVaney K, Bryskiewicz G, Blechar R, et al. Plasma-first
 49 420 resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a
 51 421 randomised trial. Lancet (2018) 392:283-91. doi: 10.1016/S0140-6736(18)31553-8
- 422 33. Ng M, Perrott J, Burgess S. Evaluation of tranexamic acid in trauma patients: A retrospective quantitative analysis. Am J Emerg Med. (2019) 37:444-9. doi: 10.1016/j.ajem.2018.06.010
- 424 34. Guo SB, Chen YX, Yu XZ. Clinical Characteristics and Current Interventions in Shock Patients in
 425 Chinese Emergency Departments: A Multicenter Prospective Cohort Study. Chin Med J (2017)
 426 130:1146-54. doi: 10.4103/0366-6999.205862

35. Heidari K, Taghizadeh M, Mahmoudi S, Panahi H, Shad EG, Asadollahi S. FAST for blunt abdominal trauma: Correlation between positive findings and admission acid-base measurement. Am J Emerg Med (2017) 35:823-9. doi: 10.1016/j.ajem.2017.01.035 36. Luehr E, Grone G, Pathak M, Austin C, Thompson S. Administration of tranexamic acid in trauma patients under stricter inclusion criteria increases the treatment window for stabilization from 24 to 48 hours-a retrospective review. Int J Burns Trauma (2017) 7:115-9 37. Naumann DN, Hazeldine J, Dinsdale RJ, Bishop JR, Midwinter MJ, Harrison P, et al. Endotheliopathy is associated with higher levels of cell-free DNA following major trauma: A prospective observational study. PLoS One (2017) 12:e0189870. doi: 10.1371/journal.pone.0189870 38. Savage SA, Zarzaur BL, Brewer BL, Lim GH, Martin AC, Magnotti LJ, et al. 1: 1 Transfusion strategies are right for the wrong reasons. J Trauma Acute Care Surg (2017) 82:845-52. doi: 10.1097/TA.00000000001402 39. Day DL, Anzelon KM, Conde FA. Association of Prehospital Shock Index and Trauma Bay Uncrossmatched Red Blood Cell Transfusion With Multiple Transfusion. J Trauma Nurs (2016) 23:89-95. doi: 10.1097/JTN.000000000000192 40. Ordonez CA, Herrera-Escobar JP, Parra MW, Rodriguez-Ossa PA, Mejia DA, Sanchez AI, et al. Computed tomography in hemodynamically unstable severely injured blunt and penetrating trauma patients. J Trauma Acute Care Surg (2016) 80:597-602. doi: 10.1097/TA.00000000000975 41. Shah AA, Rehman A, Shah SJ, Haider AH, Zogg CH, Zafar SN, et al. Abdominal gunshot wounds-a comparative assessment of severity measures. J Surg Res (2015) 198:334-9. doi: 10.1016/j.jss.2015.03.061 42. Thurston B, Chowdhury S, Edu S, Nicol AJ, Navsaria PH. Time since injury is the major factor in preventing tranexamic acid use in the trauma setting: An observational cohort study from a major trauma centre in a middle-income country. S Afr J Surg (2015) 53:13-8. doi: 10.7196/SAJS.2250 43. Sisak K, Manolis M, Hardy BM, Enninghorst N, Bendinelli C, Balogh ZsJ. Acute transfusion practice during trauma resuscitation: who, when, where and why? Injury (2013) 44:581-6. doi: 10.1016/j.injury.2012.08.031 44. Barriot P, Riou B. Hemorrhagic shock with paradoxical bradycardia. Intensive Care Med (1987) 13:203-7. doi: 10.1007/BF00254705 45. Hooper N. Armstrong TJ. Hemorrhagic Shock. (2020).https://www.ncbi.nlm.nih.gov/books/NBK470382/ [Accessed: February 25, 2021]

Page 17 of 28

BMJ Open

46. Perel P, Prieto-Merino D, Shakur H, Clayton T, Lecky F, Bouamra O, et al. Predicting early death
in patients with traumatic bleeding: development and validation of prognostic model. BMJ (2012)
345:e5166. doi:10.1136/bmj.e5166

461 47. Jávor P, Csonka E, Butt E, Rárosi F, Babik B, Török L, et al. Comparison of the previous and current
462 trauma-related shock classifications – A retrospective cohort study from a level I trauma centre. Eur
463 Surg Res (2021) doi: 10.1159/000516102

464 FIGURE LEGENDS

Fig. 1. PRISMA flow diagram. Our search strategy resulted 2017 papers. After excluding articles published before 2010 and duplicates, 1373 papers were screened based on title and abstract. In 79 cases the title clearly indicated non-eligible study design such as review or systematic review. Twenty-four title pointed out that the paper is a case report of a sole case. In 124 cases, the title clearly indicated non-eligible study population such as pregnant or pediatric. Five hundred sixteen titles revealed that the study is not closely related to our research topic. In 73 cases the title clearly indicated an animal experiment. Twenty-one records were excluded based on abstract due to a non-eligible study design such as review or systematic review. The abstract indicated a non-eligible study population such as pregnant or pediatric in 94 cases. In 110 cases, the abstract indicated that the study is not closely related to our research topic. Thirty-nine animal experiments were filtered out based on abstract. Eight studies did not have an English language abstract. In 112 cases, the abstract revealed that the study includes data that is more than 10 years old. Forty-one case reports with a patient number <10 were excluded based on abstract.

477 After excluding a total of 816 papers based on title and 425 based on abstract, 132 full-texts were assessed for eligibility. Reasons for non-inclusion of full-text articles are detailed above in the Figure.
479 Ultimately, 19 studies were enrolled to our meta-regression

- 480 *heart rate (HR) was not provided in mean or median, only the number of patients in ranges of HR (e.g.,
 481 100-120 bpm) was given
- **Fig. 2.** Risk of bias assessment.

a: The figure shows the risk of bias in the 6 main domains of the Quality In Prognostic Studies (QUIPS) assessment, in each paper. 'Study attrition' was not suitable for the retrospective studies. In 5 prospective studies, there was a moderate risk for study attrition bias. All studies were judged to carry a low risk of bias in 'Study participation' and 'Prognostic factor measurement' domains. 'Study confounding' was the worst rated domain: a moderate risk appeared in almost half of the records, in which the role of important confounders was not reported thoroughly. Based on the assessment of the 6 main domains, the overall risk of bias was determined for each study

- 58 490 **b**: The summarized risk of bias is illustrated in percentages in the main domains

- **Fig. 3.** Relation between heart rate (HR) and mortality of bleeding trauma patients. Linear association
 - 492 between HR and mortality could not be identified.
 - 493 HR=heart rate

Fig. 4. Subgroup analysis of studies on trauma patients who received blood products. Linear association

For peer teries only

- 495 between early heart rate (HR) and mortality rate of patients could not be identified.
- 12 496 HR=heart rate





Fig. 1. PRISMA flow diagram. Our search strategy resulted 2017 papers. After excluding articles published before 2010 and duplicates, 1373 papers were screened based on title and abstract. In 79 cases the title clearly indicated non-eligible study design such as review or systematic review. Twenty-four title pointed out that the paper is a case report of a sole case. In 124 cases, the title clearly indicated non-eligible study population such as pregnant or pediatric. Five hundred sixteen titles revealed that the study is not closely related to our research topic. In 73 cases the title clearly indicated an animal experiment. Twenty-one records were excluded based on abstract due to a non-eligible study design such as review or systematic review. The abstract indicated a non-eligible study population such as pregnant or pediatric in 94 cases. In 110 cases, the abstract indicated that the study is not closely related to our research topic. Thirty-nine animal experiments were filtered out based on abstract. Eight studies did not have an English language abstract. In 112 cases, the abstract revealed that the study includes data that is more than 10 years old. Forty-one case reports with a patient number <10 were excluded based on abstract.

After excluding a total of 816 papers based on title and 425 based on abstract, 132 full-texts were assessed for eligibility. Reasons for non-inclusion of full-text articles are detailed above in the Figure. Ultimately, 19 studies were enrolled to our meta-regression

*heart rate (HR) was not provided in mean or median, only the number of patients in ranges of HR (e.g., 100-120 bpm) was given

170x105mm (300 x 300 DPI)



For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml





Fig. 3. Relation between heart rate (HR) and mortality of bleeding trauma patients. Linear association between HR and mortality could not be identified. HR=heart rate

170x123mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2021-059271 on 19 October 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.






Fig. 4. Subgroup analysis of studies on trauma patients who received blood products. Linear association between early heart rate (HR) and mortality rate of patients could not be identified. HR=heart rate

170x123mm (300 x 300 DPI)

1 2	PRIS MA
3	
4	Section

PRISMA 2020 Checklist

4 Section and 5 Item # Checklist item 00 00 00 00 00 00 00 00 00 00 00 00 00	
Section and Topic Item # Checklist item book with is comparing a systematic review. book with section book with sectin	
TITLE 5 6 Title 1 Identify the report as a systematic review. 6 1 ABSTRACT 0 Abstract 2 See the PRISMA 2020 for Abstracts checklist. 2 INTRODUCTION 0 2 See the PRISMA 2020 for Abstracts checklist. 2 2 INTRODUCTION 0 2 See the PRISMA 2020 for Abstracts checklist. 2 2 Objectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. 0 3 METHODS 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. 4 4 Information 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to dentify studies. Specify the date when each source was last searched or consulted. 4 Search strategy 7 Present the full search strategies for all databases, registers and websites, including how many reviewers screened each report reliveed, whether they worked independently, and if applicable, details of automation tools used in the process. 4 Data collection process 8 Specify the methods used to collect data from reports, including how many reviewers collected data from each report enviewed, and webenet they worked indepen	ocation here item reported age nr.)
ABSTRACT ABSTRACT 2 See the PRISMA 2020 for Abstracts checklist. 2 INTRODUCTION 2 See the PRISMA 2020 for Abstracts checklist. 2 Rationale 3 Describe the rationale for the review in the context of existing knowledge. 2 Objectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. 3 METHODS 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. 4 Information 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to detentify studies. Specify the detent study and the there is a sources and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 4 Selection process 8 Specify the methods used to collect data from reports, including how many reviewers collected data from each report and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 4 Data collection 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report whice data were sought. Specify whether all results that were compatible with each sufficient tools used in the process. 4 Data collection 9 Specify the methods	
Abstract 2 See the PRISMA 2020 for Abstracts checklist. 2 INTRODUCTION 2 See the PRISMA 2020 for Abstracts checklist. 2 Rationale 3 Describe the rationale for the review in the context of existing knowledge. 2 Objectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. 2 METHODS 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. 4 Information 6 Specify all databases, registers, websites, organisations, registers and other sources searched or consulted to deentify studies. Specify the date when each source was last searched or consulted. 4 Selection process 8 Specify the methods used to decide whether a study met the inclusion criteria of the review, including any filters and limits used. 4 Data collection process 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 4 Data collection process 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report which data were sought. Specify whether all results that were compatible with each autoome domain in each study were sought (e.g. for all measures, time po	
INTRODUCTION Describe the rationale for the review in the context of existing knowledge. 2-3 Objectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. 0 3 METHODS 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. 4 Information 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to detentify studies. Specify the date when each source was last searched or consulted. 4 Selection process 8 Specify the methods used to collect data from reports, including any filters and limits used. 4 2 5 Specify the methods used to collect data from reports, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 4 2 0 5 Specify the methods used to collect data from reports, including how many reviewers collected data from each report whether all cources search and in the results of automation tools used in the process. 4 2 0 10 List and define all outcomes for which data were sought. Specify whether all results that were compatible with each guictome domain in each study are sought (e.g. for all measures, time points, analyses), and if not, the methods used t	
Rationale 3 Describe the rationale for the review in the context of existing knowledge. 2.3 Objectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. 3 METHODS 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. 4 Information 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to entity studies. Specify the date when each source was last searched or consulted. 4 Search strategy 7 Present the full search strategies for all databases, registers and websites, including any filters and limits used. 4 Selection process 8 Specify the methods used to collect data from reports, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 4 Data collection process 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 4 Data collection process 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each spuctome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the	
Objectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. 3 METHODS 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. 4 Information 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to the eview when each source was last searched or consulted. 4 Search strategy 7 Present the full search strategies for all databases, registers and websites, including any filters and limits used. 4 Selection process 8 Specify the methods used to decide whether a study methe inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 4 Data collection process 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report whether they worked independently, and if applicable, details of automation tools used in the process. 4 Data collection process 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report wither were were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. 5 Data items 10a	
METHODS Image: Constraint of the second state of the second	3
Eligibility criteria 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. 4 Information 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to definitify studies. Specify the methods used to accure was last searched or consulted. 4 Sector strategy 7 Present the full search strategies for all databases, registers and websites, including any filters and limits used. 4 Selection process 8 Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 4 Data collection 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. 5 Data items 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each automed ondain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which resulting sources). Describe any assessment 4 Study risk of bias 11 Specify the methods used to assess risk of bias in the includes, including details of automation too	
Information 6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to detentify studies. Specify the 4 Improved 4 Search strategy 7 Present the full search strategies for all databases, registers and websites, including any filters and limits used. 4 Selection process 8 Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 4 Data collection 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report wether they worked independently, and if applicable, details of automation tools used in the process. 4 Data terms 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. 5 10b List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. 4 Effect measures 12 Specify the methods used to assess risk of bias in the included studies, including details of automation tools used in the proces	
a sources date when each source was last searched or consulted. operation 19 Search strategy 7 Present the full search strategies for all databases, registers and websites, including any filters and limits used. 4 20 Selection process 8 Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 4-5 20 Data collection process 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report whether they worked independently, and if applicable, details of automation tools used in the process. 4 21 Data collection process 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. 4 22 Data items 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. 5 23 Study risk of bias 11 Specify the methods used to assess	
20 Selection process 8 Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 4-5 21 Data collection 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report whether they worked independently, and if applicable, details of automation tools used in the process. 4, independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. 4, independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. 4, independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. 4, independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. 5 20 Data items 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each exit come domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. 5 21 10b List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any methods used to asse	
21 record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 22 Data collection 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of actionation tools used in the process. 4, ' 24 Data items 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each autome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. 5 26 10b List and define all outcomes for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. 4 27 10b List and define all outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the process. 5 38 29 11 Specify the methods used to decide which studies were eligible for each synthesis or presentation of results. 5 31 Specify the methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data - 32 Synthesis 13a Describe any methods required to prepare the data for presentation o	
23 process independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. 24 Data items 10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. 5 26 10b List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. 4 29 Study risk of bias assessment 11 Specify the methods used to assess risk of bias in the included studies, including details of automation tools used in the processe 5 30 Effect measures 12 Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. 5 33 Synthesis amethods 13a Describe the processes used to decide which studies were eligible for each synthesis (item #5)). 5 34 13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data -	5
26 study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. 4 27 10b List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. 4 29 Study risk of bias assessment 11 Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the processe 5 31 Effect measures 12 Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. 5 33 Synthesis 13a Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). 5 35 13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data -	10
28 10b List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. 4 29 Study risk of bias assessment 11 Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the processe 5 30 Effect measures 12 Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. 5 33 Synthesis 13a Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). - 35 13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summer y statistics, or data -	
30 assessment each study and whether they worked independently, and if applicable, details of automation tools used in the procession in the procession <td></td>	
33 Synthesis 13a Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). - 34 methods 13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data -	
34 methods comparing against the planned groups for each synthesis (item #5)). 35 13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data -	
35 13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data -	
37 13c Describe any methods used to tabulate or visually display results of individual studies and syntheses.	
 38 13d Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. 	
40 13e Describe any methods used to explore possible causes of beterogeneity among study results (e.g. subgroup analysis meta-regression)	
41 100 Describe any matrices deed to explore possible eddeed of metrogeneity annual edge of metrogeneity and e	
43 Reporting bias 14 Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases) 5 44 assessment 5	
45 Certainty 15 Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome	



47

PRISMA 2020 Checklist

		BMJ Open	Page 24 o
PRIS	SMA 2	2020 Checklist	
Section and Topic	ltem #	Checklist item	Location where item is reported (Page nr.)
assessment			
RESULTS		۵ ۵	
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the real method in the review, ideally using a flow diagram.	5, Fig. 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were executed.	-
Study characteristics	17	Cite each included study and present its characteristics.	6 (Table 1)
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	6-7 (Fig. 2)
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	7 (Fig 3-4)
Results of	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	-
syntheses	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	-
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	-
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	-
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assess	6-7, (Fig. 2
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	-
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	7-8
	23b	Discuss any limitations of the evidence included in the review.	9
	23c	Discuss any limitations of the review processes used.	9
	23d	Discuss implications of the results for practice, policy, and future research.	9
OTHER INFORMA			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	4
P	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	4
Current	24c	Describe and explain any amendments to information provided at registration or in the protocol.	-
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	9
Competing interests	26	Declare any competing interests of review authors.	9
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; date extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	10

Pa	ge 25 of 28	BMJ Open	136/bm
1	PRIS MA	BMJ Open PRISMA 2020 Checklist MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for report n71 For more information, visit: <u>http://www.prisma-statement.org/</u>	njopen-20
2 3	From: Page	MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for report	ing systematic reviews. BMJ 2021;372:n71. doi:
4 5	10.1136/bmj	For more information, visit: <u>http://www.prisma-statement.org/</u>	5927
6			1 on
7 8			19 0
			Octob
10 11			ver 20
12 13			022.
14			Dowr
15 16			nload
17	,		ed fr
18 19			om h
20)		ttp://
21 22			b mjo
23 24			pen.t
25	;		omj.c
26 27			om/
28	3		on Ar
29 30			oril 19
31 32			9, 20
33	5		24 by
34 35			gue
36	i i		st. P
37 38			rotec
39 40			tted t
40 41			S
42 43			guest. Protected by copyright
44	ŀ		ht.
45 46		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Study: first author, year of publicati on	Data origin: institute, country	Data collection: type, date	Indicators of hemorrhage	Patie nt num ber (n)	Age (y) mean ± SD or median [IQR]	Male gend er n (%)	HR mean ± SD (PH/A D)	Mor talit y n, (%)	Main outcome(s)
Bohonek 2019	Military University Hospital Prague, Czech Republic	retrospective , single- center, 2014-2018	received blood products (fresh apheresis platelets or cryopreserved platelets)	46	53 [20– 80]; 50 [27– 66]*	32 (69.6)	94.8 ± 59.0 (AD)	10 (21. 7)	mortality, blood products administe red, adverse effects following platelet transfusio n, laborator y paramete rs such as aPTI
Boudreau 2019	University of Cincinnati Medical Center, Cincinnati, Ohio, USA	retrospective , single- center, April 2014 – October 2015	received blood products and tranexamic acid	116	45 [24- 61]; 33 [23- 45]*	90 (77.6)	101.3 ± 43.0 (PH)	27 (23. 3)	mortality, thromboe mbolic events, transfusio n requireme nts
Duchesne 2019	11 level I trauma centers, 1 level II trauma center from the USA	retrospective , multi- center, January 2011 – December 2016	pelvic fracture with SBP \leq 90 mmHg and/or HR \geq 120 bpm and/or BD \geq 5 mEq	279	40 [28- 54]	172 (62.0)	120.6 ± 27.7 (AD)	89 (32. 0)	mortality, frequency of each hemorrha ge interventi on adjunct used, time to definitive bleeding control
Montazer 2019	Imam Khomeini Hospital, Sari, Iran	prospective, single- center, March 2014 – February 2015	multiple trauma with hemodynamic instability (not defined)	400	42 ± 20	333 (83.3)	110.0 ± 14.0 (AD)	67 (16. 7)	mortality
Priestley 2019	LAC+USC Medical Center, LAC+USC blood bank database, University of	retrospective , single- center, January 2010 – October 2014	received 3 units of pRBC in any 60-minute period within 24 hours of admission and received interventional	283	34 [24- 48]	244 (86.2)	104.0 ± 24.0 (PH)	88 (31. 1)	mortality, days on ventilator , length of hospitaliz ation

	Southern California, Los Angeles, CA, USA		radiology or surgery for definitive hemorrhage control	10.0	20.0		1011		
Barmpara s 2018	Cedars-Sinai Medical Center Los Angeles, CA, USA	retrospective , single- center January 2011 – October 2016	received massive transfusion (defined as 3 units of pRBC within the first hour from admission)	120	39.0 [27.0- 54.8]	92 (76.7)	101.1 ± 39.7 (AD)	59 (49. 2)	mortalit
Chaochan kit 2018	Songklanagari nd Hospital, Hat Yai, Thailand	retrospective , single- center, January 2014 – December 2014	received massive transfusion, met trauma team activation criteria	15	35 [22- 44.5]	13 (86.7)	113.0 ± 22.1 (AD)	12 (80. 0)	need fo massiv transfus n
Moore 2018	Denver Health Medical Center, Denver, CO, USA	prospective, single- center, April 2014 – March 2017	$SBP \le 70 \text{ mmHg}$ or 71-90 mmHg with HR \ge 108 bpm	125	33 [25- 47]	103 (82.4)	110.0 ± 15.9 (PH)	16 (12. 8)	mortali
Ng 2018	British Columbia Trauma Registry, Canada	retrospective , single- center, April 2012 – June 2015	$SBP \le 90 \text{ mmHg}$ and/or $HR \ge 110$ bpm	117	43 ± 19	96 (82.0)	112.0 ± 35.0 (AD)	22 (19. 0)	meetin the indicatio criteria for TX
Guo 2017	33 academic hospitals in 16 Chinese provinces, China	prospective, multi-center, December 2013 – April 2014	new-onset hypotension unexplained by any other cause than hemorrhage (SBP < 90 mmHg, DBP < 60 mmHg, or MAP < 65 mmHg or decreased SBP with more than 40 mmHg from baseline in a hypertensive patient), and signs of tissue hypoperfusion (tachycardia, oliguria, mottled skin, altered mental state)	428	52 ± 18	296 (69.2)	111.3 ± 17.9 (AD)	104 (23. 4)	mortali
Heidari 2017	4 level I trauma centers from Iran	prospective, multi-center, April 2015 – September 2015	blunt abdominal trauma with positive FAST	168	38 ± 17	129 (76.8)	105.3 ± 23.4 (AD)	57 (33. 9)	positiv FAST mortali

(

Luehr 2017	Mercy Hospital- Springfield, Springfield, MO, USA	retrospective , single- center, 2013 - 2016	received blood products and tranexamic acid	115	42 ± 18	78 (67.8)	133.3 ± 21.4 (PH)	20 (17. 4)	mortality
Naumann 2017	University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK	retrospective , single- center, July 2015 – January 2017	received blood products, required intensive care and had a lactate value >2 mmol/l (cohort B**)	17	40 ± 18	16 (94.0)	108.0 ± 16.2 (AD)	3 (17. 6)	mortality thromboe mbolic events, hospital- free and ICU-free days (calculate d as 30 minus the number o days in hospital and ICU respective ly)
Savage 2017	Indiana University School of Medicine, Indianapolis IN, USA; The University of Tennessee Health Science Center, Memphis, TN, USA	retrospective , multi- center, September 2013 – May 2015	received at least one unit of pRBC within the first 24 hours of admission	330	35 [25- 54]	251 (76.0)	108.2 ± 55.3 (AD)	82 (24. 8)	mortality
Day 2016	The Queen's Medical Center, Honolulu, Hawaii, USA	retrospective , single- center, September 2011 – March 2013	received at least one unit of pRBC in the first 6 hours, met trauma team activation criteria	116	no data	no data	98.0 ± 24.0 (PH)	13 (11. 0)	multiple transfusio ns
Ordoñez 2016	Fundación Valle del Lili, University Hospital, Cali, Colombia	retrospective , single- center, January 2012 – December 2013	ISS > 15 with hemodynamic instability (SBP < 100 mmHg and/or HR > 100 bpm and/or the need for at least 4 units of packed red blood cells in the trauma bay)	171	32 ± 14	154 (90.0)	112.6 ± 23.5 (AD)	26 (15. 2)	mortality
Shah 2015	Aga Khan University Hospital, Karachi, Pakistan	retrospective , single- center, January 2011 – December 2012	isolated abdominal gunshot wound	70	35 ± 11	68 (97.1)	99.8 ± 30.3 (AD)	11 (15. 7)	mortality complica ions

Thurston	Trauma	prospective,	SBP < 90 mmHg	50	32 ± 13	47	123.3	11	mortality
2015	Center, Groote	single-	and/or HR >110			(94.0	± 13.1	(22.	
	Schuur	center,	bpm at any time)	(AD)	0)	
	Hospital and	September	from admission						
	Faculty of	2013 -	to 3 hours after						
	Health	November	injury						
	Sciences,	2013							
	University of								
	Cape Town,								
	South Africa								
Sisak	John Hunter	prospective,	received blood	91	38 [22-	68	100.0	13	mortality,
2013	Hospital and	single-	products within		59]	(74.7	± 30.1	(14.	need for
	University of	center,	the first 24 hours)	(AD)	0)	emergent
	Newcastle,	January	from admission						surgery,
	Newcastle,	2010 –							ICU
	NSW, Australia	January							admission
		2011							, length of
									ICU-and
									hospital
									stay

Table S2. Detailed description of the characteristics of the included studies. Most papers enrolled trauma patients receiving blood products and/or showing signs of hemodynamic instability. Hemodynamic instability was defined by vital parameters in most cases. Most of the data was collected retrospectively. The number of participants in each dataset ranged from 15 to 428. There is a significant heterogeneity in mortality between datasets. The need for massive transfusion is accompanied by a prominently high mortality rate. A mean heart rate (HR) > 120 bpm does not entail an outstanding mortality rate. *the study population was divided into two groups, median [IQR] age values were provided separately

for the groups

**only cohort B consisted of trauma patients with active bleeding

SD=standard deviation, IQR=interquartile range, aPTI=activated partial thromboplastin time, ICU=intensive care unit, PH=prehospital, AD=upon admission, pRBC=packed red blood cells, RCT=randomized controlled trial, SBP=systolic blood pressure, DBP=diastolic blood pressure, MAP=mean arterial pressure, ISS=injury severity score, HR=heart rate, bpm=beats per minute, BD=base deficit, FAST=focused assessment with sonography for trauma, TXA=tranexamic acid